Neurology – Altru Health System – Grand Forks, ND

Posted on by

Altru's neurology team focuses on the prevention, diagnosis and treatment of disorders of the body's nervous systems. Our team is made up of board certified physicians, neurosurgeon and a nurse practitioner, along with support staff.

To contact Altru's Neurology Department, please call 701.780.2300.

Medical care may include:

You may need to see a neurologist if you have been examined by a primary care physician and told that your symptoms are neurological in nature. Your primary care physician will consult a neurologist and schedule an appointment for an exam and possible tests. Once your exam and tests are completed, the neurologist will work with you to determine the plan or care which may include medication or therapy services.

In some cases, you may be referred to our neurosurgeon, if surgery seems most beneficial.

A neurosurgeon is responsible for the correction of disorders of the body's nervous system through surgery.

Altru's experienced, board-certified neurosurgeons perform surgical procedures on delicate parts of the body, including the brain, spine and individual nerves.

Working closely with Altru's neurologists, our team provides the best care possible to individuals affected by nerve disorders and diseases.

For information, please call 701.780.6427.

Altru's Multiple Sclerosis (MS) Specialty Clinic includes a day scheduled with multiple appointments of various specialists and services individualized for each patient. In addition to seeing the neurologist and nurse practitioner, patients will often be scheduled with a physical therapist, occupational therapist, speech language pathologist and a social worker/case manager. They may also be scheduled to see other specialists such as a dietitian for nutrition therapy, and have appointments with a urologist, optometrist or other physician's. Each patient's schedule is tailored to their specific needs

Altru's Multiple Sclerosis Specialty Clinic offers many advantages for our patients all in one convenient location, Altru 1300 Columbia.

To learn more about Altru's Multiple Sclerosis Specialty Clinic, call 701.780.2315.

See the article here:
Neurology - Altru Health System - Grand Forks, ND

Neurology | Seminars in Neurology – thieme.com

Posted on by

Subscribe today and receive up to 20% off your first year's subscription! Applies for Individuals only.

IMPACT FACTOR 2018: 1.473

Seminars in Neurology is a review journal on current trends in the evaluation, diagnosis, and treatment of neurological diseases. Areas of coverage include multiple sclerosis, central nervous system infections, muscular dystrophy, neuro-immunology, spinal disorders, strokes, epilepsy, motor neuron diseases, movement disorders, higher cortical function, neuro-genetics and neuro-ophthamology. Each issue is presented under the direction of an expert guest editor, and invited contributors focus on a single, high-interest clinical topic.

Up-to-the-minute coverage of the latest information in the field makes this journal an invaluable resource for neurologists and residents.

Manuscript Submission All manuscripts must be submitted exclusively via online submission at http://mc.manuscriptcentral.com/sin

2019 Topics Include:

Emergency NeurologyDementia

Abstracting and indexing:

Journal Citation Reports (JCR), Emerging Sources Citation Index (ESCI), Biological Abstracts, BIOSIS, Current Contents/Clinical Medicine, EMBASE, Excerpta Medica, Index Medicus, MEDLINE, Neuroscience Citation Index, Research Alert, Scopus, Scisearch, EBSCO, ProQuest

Individual Rates: Personal subscription orders can only be placed by individuals and must include the recipient's name and personal address. Must be for individual use only and paid for by personal funds of the individual. Only qualified professionals and students are eligible for individual subscriptions.

For institutional subscriptions, please contact Institutional Sales for pricing at:

Please read our complete Terms of Trade for journal subscription policies.

Journal subscribers will receive a separate invoice and confirmation for your subscription order with taxes broken down separately as applicable and appropriate for your region.

Read more here:
Neurology | Seminars in Neurology - thieme.com

Adult Neuropsychology Postdoctoral Fellowship | For …

Posted on by

The primary focus of the Adult Neuropsychology Postdoctoral Fellowship at University Hospitals Cleveland Medical Center is to provide advanced training and education in the competencies necessary for the specialized practice of clinical neuropsychology. At the completion of the program, fellows should be capable of independent patient care, research and teaching in a range of settings including academic medical centers, hospitals and private practice.

The program is housed within the Department of Neurology at UH Cleveland Medical Center. UH Cleveland Medical Center is a 1,032 bed, nonprofit medical center in the University Circle neighborhood of Cleveland, Ohio, and is one of the primary teaching hospitals of Case Western Reserve University School of Medicine. UH Cleveland Medical Center is the anchor hospital of the University Hospitals Health System, which includes an integrated network of 18 hospitals, more than 40 outpatient health centers, 4,700 medical providers and more than 26,000 employees. The Department of Neurology is included within the Neurological Institute of University Hospitals and comprises 55 faculty across nine sites. Neurology houses multiple Centers of Excellence including Brain Health and Memory; Epilepsy; Movement Disorders; Stroke and Cerebrovascular Disorders; Critical Care Neurology; Community Neurology; and others. The Department of Neurology supports a large residency training program (12 per year for a total of 48 residents) and fellowship programs in Adult Neuropsychology, Pediatric Neurology, Neuromuscular Medicine, Vascular Neurology, Epilepsy, Clinical Neurophysiology (EEG) and Neurologic Intensive Care. UH Cleveland Medical Center is a thriving academic center. It houses an active clinical trials unit in neurology and has been ranked among the top 20 programs in the country for National Institutes of Health funding several consecutive years.

UH Cleveland Medical Center is consistently recognized as one of the nation's best hospitals by U.S. News & World Report. In 2016 2017, UH Cleveland Medical Center was named among the countrys Top 50 in eight methodology-ranked specialties including neurology and neurosurgery. These results place UH Cleveland Medical Center in the top 1 percent of the nations 5,000 hospitals eligible for ranking every year. In addition to the exceptional care provided to patients, resident and fellowship training is included among the primary initiatives of University Hospitals, aligning with its mission: To Heal. To Teach. To Discover.

The primary site for training in the Adult Neuropsychology Postdoctoral Fellowship Program is the UH Cleveland Medical Center Department of Neurology. However, patients are also seen at several satellite clinics around the Greater Cleveland area. Many of the services that the Neuropsychology Program provides involve a multidisciplinary, team-based approach and include frequent interactions with other specialist providers, both informally and in formal case conference formats. Fellows will also have opportunities for multidisciplinary team participation in the areas of dementia/memory loss, deep brain stimulation, epilepsy, normal pressure hydrocephalus, sports-related concussion and mild traumatic brain injury, among others.

Offices for faculty and fellows are located on the campus of UH Cleveland Medical Center. Each fellow is provided with a personal work space and his or her own computer/laptop. Fellows also have access to the medical library and online journals through UH Cleveland Medical Center.

The client populations served by the Department of Neurology are quite diverse in age, socioeconomic status and cultural background. The fellow will develop experience with clinical populations that include all forms of dementia and memory loss; deep brain stimulation and movement disorders; epilepsy and epilepsy surgery; normal pressure hydrocephalus; attention deficit hyperactivity disorder; learning disabilities; concussion and mild traumatic brain injury; traumatic brain injury; cerebrovascular disease and stroke; multiple sclerosis; neuro-oncology; and other conditions/syndromes. The fellows primary responsibilities will be diagnostic interviewing, neuropsychological assessment, and report writing; however, a substantial portion of the fellows schedule is blocked for didactics and research activities.

Although fellows will gain experience with a wide range of neurological conditions and patient populations, the Adult Neuropsychology Postdoctoral Fellowship at UH Cleveland Medical Center has four primary clinical service emphases: behavioral neurology, concussion management, general neurology and pre-surgical evaluation.

The Brain Health and Memory Center services at UH Foley ElderHealth Center provides care for the older adult patient. As part of a multidisciplinary team that also includes neurologists, geriatricians, nurse practitioners, nurses and social workers, neuropsychology plays an essential role in providing comprehensive outpatient care for this patient population. Neuropsychology fellows will have the opportunity to participate in UH Foley ElderHealth Centers integrated patient care model and gain experience with diverse patient populations. Referral questions/differential diagnosis often includes, but is not limited to, mild cognitive impairment and mild neurocognitive disorder; Alzheimers disease (including early onset); frontotemporal dementia; vascular dementia; lewy body dementia; posterior cortical atrophy; primary progressive aphasia; rapidly progressing conditions such as prion disease; Parkinsons disease; Huntingtons disease; multiple sclerosis; traumatic brain injury; stroke; and other medical, psychiatric and substance use disorders. Fellows will participate in individual feedback sessions with patients and their families and may also participate in summary visits alongside the referring neurologist/geriatrician and social worker on a case-by-case basis.

Fellows will also have the opportunity to engage in clinical didactic training experiences with UHs nationally recognized expert behavioral neurologists, Brian Appleby, MD, and Alan Lerner, MD. Opportunities for education and involvement in clinical research programs will be available including projects to examine prion diseases such as Creutzfeldt-Jakob disease and young-onset dementias in collaboration with the National Prion Disease Pathology Surveillance Center at Case Western Reserve University School of Medicine. Opportunities for involvement in multiple ongoing clinical trials through UH Foley ElderHealth Center will also be provided. These clinical trials are to explore new treatments for neurodegenerative conditions as well as caregiver education, methods and resources. For additional information about our behavioral neurology services, visit the Brain Health and Memory Center website.

The UH Concussion Management Program is a neuropsychologist-led, multidisciplinary, collaborative effort that provides comprehensive concussion care in order to safely return both sports and non-sports patient populations back to sports, school and work. UH Sports Medicine covers a large population of athletes in Northeast Ohio at all levels of athleticism including numerous youth leagues, 47 high schools and seven colleges/universities. We are also affiliated with several professional organizations including the Cleveland Browns (National Football League). In 2014, UH became one of only two Level I trauma centers in the Cleveland area, providing opportunities to work with patients who have sustained a wide range of neurological injuries of varying severity, including head trauma. Neuropsychological evaluation is an integral part of the concussion management process, with referrals coming at all phases of recovery depending on patient needs and concussion protocols.

Neuropsychological fellows will gain invaluable experience with multidisciplinary concussion management teams, concussion at all levels of sport, diverse populations and multiple contexts of injury. Our neuropsychology faculty are nationally recognized experts in the field of sports neuropsychology and have been active in establishing sports concussion legislation in Ohio as well as providing education regionally and nationally on concussion-related topics. Opportunities for concussion research are also be available for fellows, with our neuropsychology faculty currently acting as PI on multiple research investigations on concussion-related topics such as evaluating the use of subthreshold exercise in post-concussion syndrome; evaluating the effectiveness of youth concussion testing; evaluating new and leading-edge technologies for the diagnosis and management of concussion; and more. For further information, visit the UH Concussion Management Program website.

The Neuropsychology Program at University Hospitals receives referrals for comprehensive evaluation primarily from Centers of Excellence within UH Neurological Institute. However, additional referrals are received from other UH institutes and from outside institutions. UH Neurological Institute comprises a team of nationally recognized experts delivering comprehensive, coordinated care for disorders of the brain and nervous system. Recognized by U.S. News & World Report as one of the finest neurology and neurosurgery programs in the country, UH Neurological Institute includes 14 Centers of Excellence that provide individualized treatment, innovative techniques and access to some of the most innovative research designed to advance the science of neurological medicine.

For the Neuropsychology Program, the most common referral questions include differential diagnosis of neurodegenerative disorders and documentation of deficits associated with neurological diseases including stroke, head injury, neuro-oncology diseases, neurodegenerative diseases and many others. Neuropsychology fellows have the opportunity to complete outpatient neuropsychological evaluations of patients with a wide variety of referral questions and neurological diagnoses as well as opportunities to participate in integrated treatment teams. For more information, visit UH Neurological Institutes website.

Neuropsychology is a fully integrated and critical component of the deep brain stimulation (DBS), epilepsy surgery and normal pressure hydrocephalus (NPH) programs at University Hospitals. Neuropsychological evaluation is required at a patients pre-surgical evaluation and as part of post-surgical outcome monitoring for each service. Neuropsychology fellows and faculty meet weekly or biweekly with our surgical treatment teams to review neurocognitive findings in conjunction with other sources of data including the neurological and neurosurgical exam, EEG and neuroimaging results, levodopa response testing, and others. The team collaboratively determines appropriate interventions and plans for patients, with fellows obtaining invaluable experience in working with multidisciplinary treatment teams, presenting neuropsychological data to providers in related fields and working with diverse neurological populations.

Each of these programs is nationally recognized and led by faculty who are renowned as leaders in their respective fields.

For additional information on the UH Parkinsons & Movement Disorders Center, including the DBS program, visit our website.

For more information about the UH Epilepsy Center, including the epilepsy surgery program, visit our website.

For further information on NPH and other related services, visit our Brain Health & Memory Center website.

Read the rest here:
Adult Neuropsychology Postdoctoral Fellowship | For ...

Neurology | Vancouver Clinic

Posted on by

Is there a cure for Alzheimers disease?

Some Alzheimers disease medications and management strategies may temporarily improve symptoms, thereby helping people with Alzheimers gain greater independence and maintain a good quality of life. However, there is no cure for Alzheimers disease, and its important to seek supportive services as early as possible.

An athletes prior history of concussions is perhaps the biggest risk factor related to his or her risk for another concussion. Research shows that if someone has already suffered one concussion, they are one- to two-times more likely to suffer another. The more concussions they suffer, the more their risk goes up.

Studies also show that females are more likely than males to sustain concussions, and that they require more recovery time. This is most likely due to a number of anatomical and biomechanical differences between genders.

Lastly, a history of developmental disorders, psychiatric disorders, or headaches/migraines can play a part in concussion recovery time. Since new research on concussions is always coming out, its important that coaches, trainers, parents, and athletes themselves stay up-to-date on information related to prevention and treatment.

First, there is a strong correlation between changes to your vision and the brain. For instance, strokes, aneurysms, brain tumors and even a brain infection can cause visual problems.

With that said, your first stop should be to either check in with an eye doctor, or consult your family physician. Plenty of visual problems are related to the eye itself, such as cataracts, glaucoma or astigmatism. If, after an eye exam, everything checks out, or if the problem includes other issues such as dizziness or migraines, make an appointment with the neurology department right away.

Neurologists do not perform surgery, but can recommend surgical treatment and refer patients to the appropriate surgeon if necessary.

Read the original post:
Neurology | Vancouver Clinic

Neurology Conferences | Neurologists Conferences …

Posted on by

Sessions/Tracks

On behalf of the Organizing Committee it is our pleasure to invite you to Neurology conference entitled21stWorld Congress on Neurology and TherapeuticsduringMarch 15-17, 2018atLondon, UK

Neurology 2018has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Committee.

Live format of the conference will be Accredited withCMEandCPDCredits

Neurological disordersare diseases of the brain, spine and the nerves that connect them. There is ample evidence that pinpoints neurological disorders as one of the greatest threats to public health. There are more than 600 diseases of the nervous system, such as Alzheimer's disease,brain tumors, epilepsy,Parkinson's disease, and stroke as well as less familiar ones such as frontotemporal dementia and an estimated 6.8 million people die every year as a result of these disorders there by making it necessary to investigate the unresolvedNeurological Disorder.

Track on:Migraine and Neuropathic pain

Neuropathic pain(neuralgia) is a pain that comes from problems with signals from the nerves. It was mainly classified into peripheral neuropathic pain and central neuropathic pain which includesspinal cordinjuryand central disorders. Pain is a significant public health problem that costs society at least and560-and635 billion annually. Women were more likely to experiencepainin comparison to men. According to the recent survey, Chronic Pain affects 47% of USA Adults. The main intent of this session is to understand Complex regional pain syndrome (CRPS) that is associated with dysregulation ofCentral Nervous System(CNS) and Autonomic Nervous System (ANS). The current session on clinical neurology and pain focuses on: Neurological conditions affecting people and treatment of neurological or personality disorders.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy, Neuro Informatics, Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

Brain Aneurysm FoundationandBrain InjuryAssociation of America, Inc.,EpilepsyFoundation and Epilepsy Institute,Huntington's Disease Society of America and Hydrocephalus Association,International Dyslexia Association and International Essential Tremor Foundation,International Rett Syndrome Foundation and IntracranialHypertensionResearch Foundation.Children'sBrain DiseaseFoundation,Myelin Repair Foundation and Myositis Association.

Track on:Neurodegenerative Disorders and Stroke

Neurodegeneration or neuron death is the progressive loss of structure or function ofneuronswhich includes disorders like Alzheimers disease, Parkinsons disease etc. In the United States, near about 60,000 cases of Parkinsons disease are diagnosed per year. The 3rd leading cause of death after cancer and heart disease is Stroke, thereby focusing on the epidemiology ofstrokeand risk factors. The main classification of stroke is haemorrhage stroke and ischemic stroke. The areas highlighted for discussion in this session are: Motor neuron diseases and Ataxias,Alzheimers Disease, Mechanism and Diagnosis, Novel Insights and Therapeutics for Parkinsons disease and Amyotrophic lateral sclerosis. Further we will discuss more about the various diagnosis procedure,Imagingtechnique, and acute stroke management,

Associations on Neurology

Migraine Research Foundationand MitoAction,NBIA Disorders Association and Neurofibromatosis Network,Brain Injury Resource Center and Brain Trauma Foundation,Epilepsy Therapy Project and Exceptional Parent Magazine,Huntington's Disease Society of Americaand Hydrocephalus Association,Multiple Sclerosis Association of America Multiple Sclerosis Foundation,Multiple System Atrophy Coalition, The MUMS National Parent-to-Parent Network

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

Neuropathy Associationand Nevus Outreach, Inc,Brain Injury Resource Center and Brain Trauma Foundation,Epilepsy Therapy Project and Exceptional Parent Magazine,Huntington's Disease Society of America Hydrocephalus Association,Multiple Sclerosis Association of Americaand Multiple Sclerosis Foundation,Multiple System Atrophy Coalition, Theand MUMS National Parent-to-Parent Network

Track 3:Neuropediatrics and Neurorehabilitation

Paediatricneurologyevaluates children with disorders of the central and peripheral nervous systems. A large proportion in US population suffers from autism, mental retardation, dyslexia, seizures and other developmental disabilities. Approximately 1,300 U.S children experience severe or fatalbraintrauma from child abuse.Epilepsyis the fourth commonneurological disorderin the US after migraine, stroke, and Alzheimers disease. So there is a need to take into account, the following diseases to dissertate: congenital hydrocephalus,Autism, Neonatal encephalopathy, Paediatrics tumour, Neurodevelopment disorder, Epilepsy and Child psychological disorders.

Neurorehabilitation is a complex medical process which aims to aid recovery from a nervous system injury. Rehabilitation is an access to reduce brain abscesses thereby increasing the Neural Repair. Neurological rehabilitation program is aimed to create awareness about the neural disorders and its diagnosis.Physiotherapyand remediation is a novel approach that remediates impairments and promotes mobility. Conference on Neurology and Therapeutics is an effort to address all areas towardsNeurorehabilitationand Neural Repair.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

Brain Aneurysm Foundation andBrain InjuryAssociation of America, Inc.,EpilepsyFoundation and Epilepsy Institute,Jain Foundation and John Douglas FrenchAlzheimer'sFoundation,Children'sBrain DiseaseFoundation,Myelin Repair Foundation and Myositis Association,Migraine Research Foundationand MitoAction,NBIA Disorders Association andNeurofibromatosisNetwork

Track 4:Neuroinfections and Neuroimmunology

Neuroimmunology is a field of neuroscience, combining immune system and thenervous system. The immune system administer defence against these organisms, inefficiency of the same results in Infections. The condition is much worse in developing countries; it has been a significant health problem in Australia. Some 350,000 to 500,000 patients suffer from multiple sclerosis (MS) in the United States .The conference onneurologyis a platform to put our heads together and thrash out the cause of Multiple sclerosis and auto immune neuropathies,Neuroimmunologicalinfectious disease, Neuromicrobial disorders and Neurological Lyme diseases, Neuroinflamation, Neuroimmuno genetics. This session also includes to group think the alteration inneuromodulationand psychiatric diseases and the recent Drug development in the field of Neuro immunology.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

Muscular Dystrophy Association and Musella Foundation forBrain TumorResearch and Information,Myasthenia Gravis Foundation of America, Inc. and Myelin Project, Myotonic Dystrophy Foundationand Narcolepsy Network, Inc.,Neuropathy Association and Nevus Outreach, Inc,National Organization on Disability and NationalParkinsonFoundation, National Patient Travel Center and NationalRehabilitationInformation Center

Track 5:Alzheimers Disease and Dementia

The brain immediately confronts us with its great complexity.Alzheimer'swhich is a type of Dementia is: An Underlying Disease that causes problems with memory,behaviourand thinking. As estimated,5.3 million Americans of all ages haveAlzheimer's diseasein the recent survey. AD is the sixth leading cause of death in the United States and the fifth leading cause of death in Americans of age 65 and older. The etiological factors, other than older age includesgeneticsusceptibility. so it is important to exchange views on Causes and Prevention of Alzheimers, Alzheimers Disease Diagnosis and Symptoms, Alzheimers Disease Pathophysiology and Disease Mechanisms, Care Practice and Awareness. we are also going to analyse the Alzheimers Disease Imaging , Mechanisms for Treatment andTherapeuticTargets.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, GermanyAssociations on Neurology

Muscular Dystrophy Association and Musella Foundation forBrain TumorResearch and Information,Myasthenia Gravis Foundation of America, Inc and Myelin Project, Myotonic Dystrophy Foundation and Narcolepsy Network, Inc.,Neuropathy Association and Nevus Outreach, Inc,National Organization on Disability and NationalParkinsonFoundation, National Patient Travel Center and NationalRehabilitationInformation Center

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

Muscular Dystrophy Association and Musella Foundation forBrain TumorResearch and Information,Myasthenia Gravis Foundation of America, Inc. and Myelin Project, Myotonic Dystrophy Foundation and Narcolepsy Network, Inc.,Neuropathy Association and Nevus Outreach, Inc,National Organization on Disability and NationalParkinsonFoundation,National Patient Travel Centerand NationalRehabilitationInformation Center

Track 6:Neuromuscular Disorders

Neuromuscular disorders is known to affect the nerves that control the voluntary muscles. One of the causes is thegeneticand immune system disorder. More than a million people in the United States are affected by some form ofneuromusculardisease, and about 40 percent of them are under age18.Diagnosis includes a multi-step process like muscle biopsy, NCV test, biochemical, genetic test etc. The goal of this session is to understand the origin of spine muscular atropies,Musculardystrophy, Lambert-Eaton syndrome and other neuromuscular junction disorder. Further there will be an interactive conversation on Spasticy, Hyper reflexia and its prevention. In addition a talk will be deliberated on Is it true that High dose ofantibioticsleads to neuromuscular junction mal function and the findings in the field of neuromuscular medicine.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

Brain Aneurysm Foundation andBrain InjuryAssociation of America, Inc.,EpilepsyFoundation and Epilepsy Institute,Jain Foundation and John Douglas FrenchAlzheimer'sFoundation,Children'sBrain DiseaseFoundation,Myelin Repair Foundation and Myositis Association,Migraine Research Foundationand Mito Action,NBIA Disorders Association andNeurofibromatosisNetwork

Track 7:Neuroimaging and Brain Engineering

What seems astonishing is that engineering techniques likebrainengineering, or Neural tissue engineering can be used to understand, repair, replace, enhance, or otherwise exploit the properties of neural systems and Neurocomputing is the study of brain function in terms of the information processing properties of the structures that make up the nervous system. current researches in the field of neuroengineering include: Neural imaging and neural networking,Biomoleculartherapies in neural regeneration,Neurorobotics, Biological neural networking, Neuro hydrodynamics and clinical treatment, Engineering strategies for repair, Computational clinical neuroscience, biological-neuronmodelling, Behaviors of networks and advanced therapies. People will also be enlightened on Advancement in brain computer interface and deep brain stimulation.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

International Rett Syndrome FoundationandIntracranialHypertensionResearch Foundation, Intractable Childhood Epilepsy AllianceandIron Disorders Institute, ISMRD-International Advocate For Glycoprotein Storage Diseases and Jacob's Cure, Inc,Caregiver Action NetorkandCarter Centers forBrain Researchin Holoprosencephaly,Cerebral Palsy Foundationand CHADD - Childrenand Adults with Attention-Deficit/Hyperactivity Disorder,Charcot-Marie-Tooth AssociationandCharlie Foundation for Ketogenic Therapies,Chiariand Syringomyelia FoundationandChildhood BrainTumorFoundation

Track 8:Neurosurgery and Neural Circuits

While the topic sounds pretty small, but we needs more speciality and critical care in this discipline. An estimated 69,720 new cases of primarybrain tumorsare expected to be diagnosed in 2013, that includes both malignant (24,620) and non-malignant(45,110) brain tumors. Basing on the prevalence of diseases, the conference focuses on Post-surgical neuralgias, Brain tumour and metastatis, Oncologicalneurosurgery, Spine neurosurgery, Neuroanaesthesia and surgery and Vascular malfunctions and surgery . The neurons are organized into ensembles called Anatomical and functionalneuralcircuits. Current researches identify disorders that affect different components of that neural circuit and a set of neural circuits that are critically involved in a specific disorder. Highest incidence rate of primary intracranial tumor was in Europe and the lowest rate in Africa. So it is requisite to enhance our knowledge on Currentneurosurgerymethod.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

International Rett Syndrome Foundationand IntracranialHypertensionResearch Foundation, Intractable Childhood Epilepsy Allianceand Iron Disorders Institute, ISMRD-International Advocate For Glycoprotein Storage Diseasesand Jacob's Cure, Inc, Caregiver Action Netork and Carter Centers forBrain Researchin Holoprosencephaly, Cerebral Palsy Foundationand CHADD - Childrenand Adults with Attention-Deficit/Hyperactivity Disorder, Charcot-Marie-Tooth Association and Charlie Foundation for Ketogenic Therapies, Chiari and Syringomyelia Foundationand Childhood BrainTumorFoundation

Track 9:Neuropharmacology

Increase in technology and our understanding of the nervous system has lead to the development ofdrugsand medicines in the two main branches i.e. molecular and behavioural beyond our imagination that has continued to rise with an increase in drug specificity and sensitivity. current topic to be discussed are New pharmacological approaches for treatment ofneuraldisorders, drug development in cell signalling and synaptic spasticity, and the latest advancement in neuropharmacologcaltherapyand drug development in this particular sector. The present conference also aims to educate the researchers on Neuroimmuno pharmacology and Interfearance of pharmacological agents in neural disorder mechanism.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

International Rett Syndrome Foundationand IntracranialHypertensionResearch Foundation, Intractable Childhood Epilepsy Allianceand Iron Disorders Institute, ISMRD-International Advocate For Glycoprotein Storage Diseasesand Jacob's Cure, Inc, Caregiver Action Netork and Carter Centers forBrain Researchin Holoprosencephaly, Cerebral Palsy Foundationand CHADD - Childrenand Adults with Attention-Deficit/Hyperactivity Disorder, Charcot-Marie-Tooth Association and Charlie Foundation for Ketogenic Therapies, Chiariand Syringomyelia Foundationand Childhood BrainTumorFoundation

Track 11:Neurogenetics

Genes affect the wiring and workings of thebrain, which is the authority of all our rides. It is ultimately and solely the genes that give rise to a particular type of protein that may be beneficial or harmful that reflects the need of research in this particular field. 6000 and more emerginggenetic disordersaccount for a significant portion of human disease and conditions. Nearly 4 percent of the approximately 4 million babies born each year have a genetic disease or major birth defect. Around 15,000 Americans are diagnosed to haveHuntingtonsdisease (HD).Keeping the same in view the following sub tracks are designed to enlighten the thoughts related to Huntington's disease (HD) and related genetic disorder, Genetic engineering to overcome neurological problems, The genes as a link between the brain andneurologicaldiseases, Gene defect and diseases, studies on genome wide association and disease diagnostics, sequencing of gene as a tool in determining the abnormal gene loci, Mutation of gene and neuronal migration defect.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

International Rett Syndrome Foundationand IntracranialHypertensionResearch Foundation, Intractable Childhood Epilepsy Allianceand Iron Disorders Institute, ISMRD-International Advocate For Glycoprotein Storage Diseasesand Jacob's Cure, Inc, Caregiver Action Netork and Carter Centers forBrain Researchin Holoprosencephaly, Cerebral Palsy Foundationand CHADD - Childrenand Adults with Attention-Deficit/Hyperactivity Disorder, Charcot-Marie-Tooth Association and Charlie Foundation for Ketogenic Therapies, Chiariand Syringomyelia Foundationand Childhood BrainTumorFoundation

Track 11:Autonomic and Central Nervous System

Autonomic disorders may result from other disorders that damage autonomicnervesor they may occur on their own. Progressive autonomic failure usually becomes apparent in the sixth decade of life. The Working of the central nervous system has proved to be more and more extensive and more and more fundamental as experiment has advanced in examining it. CNS disorder can be eithermyelopathyor encephalopathy.

Specified disorders to be discussed under this category are: Bipolar disorder, Migraine and Neuropathic pain syndromes, Accessory nerve disorder, Autonomic dysreflexia and neuropathy, CNS disorder and structural defects, Facial nerve paralysis andMeningitis.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

International Rett Syndrome FoundationandIntracranialHypertensionResearch Foundation, Intractable Childhood Epilepsy AllianceandIron Disorders Institute, ISMRD-International Advocate For Glycoprotein Storage Diseasesand Jacob's Cure, Inc,Caregiver Action NetorkandCarter Centers forBrain Researchin Holoprosencephaly,Cerebral Palsy Foundationand CHADD - Childrenand Adults with Attention-Deficit/Hyperactivity Disorder,Charcot-Marie-Tooth AssociationandCharlie Foundation for Ketogenic Therapies,Chiariand Syringomyelia FoundationandChildhood BrainTumorFoundation

Track 12:Clinical Neurology and Neuropsychiatry

It is admirable to discuss about clinical neuroscience as this focuses on the fundamental mechanisms of diseases and disorders of the brain and central nervous system and seeks to develop new ways of diagnosing such anarchy, leading to the development of novelmedication. As per the estimates by the World Health Organization, neural disorders affect over 1 billion people worldwide, constitute 12% of the burden of disease globally, and cause 14% of global annihilation.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

International Rett Syndrome Foundationand IntracranialHypertensionResearch Foundation, Intractable Childhood Epilepsy Allianceand Iron Disorders Institute, ISMRD-International Advocate For Glycoprotein Storage Diseasesand Jacob's Cure, Inc, Caregiver Action Netork and Carter Centers forBrain Researchin Holoprosencephaly, Cerebral Palsy Foundationand CHADD - Childrenand Adults with Attention-Deficit/Hyperactivity Disorder, Charcot-Marie-Tooth Association and Charlie Foundation for Ketogenic Therapies, Chiariand Syringomyelia Foundationand Childhood BrainTumorFoundation

Track 13:Neurotherapeutics, Diagnostics and Case Studies

Various neurology conferences are held all over the world like world congress ofneurology2015 Chile in order to enhance and empower the knowledge of neuroscience. The 5th International conference on neurology and therapeutics that will be held at Madrid in March 2017, addresses all areas pertinent to this endeavour concentrating on NovelTherapeuticsand Diagnostics at the cellular and molecular level. There is a profound increase in the diagnostics procedure and drug discovery in the field of Neurology.

In order to accelerate the discovery of novel diagnostic therapy, the gathering of researchers is encouraged in order to discuss on the themeStem cellsin neurological disorder and treatment, Nerve injury and repair, Sleep disorders and headache,Neurogenesis, and last but not the least new therapeutics evolved for neurological disorders

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

Brain Injury Resource Center and Brain Trauma Foundation,Epilepsy Therapy Project and Exceptional Parent Magazine,Huntington's Disease Society of Americaand Hydrocephalus Association,Multiple Sclerosis Association of Americaand Multiple Sclerosis Foundation,Multiple System Atrophy Coalition, Theand MUMS National Parent-to-Parent Network

Track 14:Neurological Nursing

Neurological Nursing is a very challenging nursing specialty dealing with assessment, nursing diagnosis, and management of many neurological disorders in which nurses provide patient care. A Neuroscience Nurse assists patients with brain andnervous systemdisorders which includes trauma,brain injuries, stroke,seizures, tumours, headaches, infections, and aneurysms, as well as a host of other neurological complexities.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

View original post here:
Neurology Conferences | Neurologists Conferences ...

Neurology Conferences 2018 | Neurology Congress 2018 …

Posted on by

International Conference on Neurology and Brain Disorders 2017 Report:

Magnus Group takes a great pride in announcing the International Conference on Neurology and Brain Disorders (INBC 2017) which was held in Valencia, Spain, during 26-28 June, 2017.

Neurology Congress 2017 witnessed a combination of peerless speakers who enlightened the crowd with their knowledge and confabulated on various new fangled issues related to the field of Neurology. The extremely illustrious conference hosted by Magnus Group was marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing their countries around the world.

For INBC 2017 Final Program: Click Here

The conference aimed with a theme Advancements and Challenges in Neurosciences & Brain Disorders. The summit engrossed a vicinity of sensible discussions on subjects like Neurodegenerative disorders, Behavioural Neurology, Neuropsychiatry, Paediatric Neurology, Neurological Disorders and Stroke, Neuroimmunology and Neurological Infections, Epilepsy & Seizure Disorders. The three days event implanted a firm relation of upcoming strategies in the field of Neurology, Neurodegenerative Disorders and Neurological Disorders and Stroke with the scientific community. The conceptual and valid knowledge shared, will also raise organizational collaborations to develop scientific accelerations.

For INBC 2017 Gallery: Click Here

Organizing Committee INBC 2017:

Giuseppe Scalabrino, University of Milan, Italy

Harry W.M. Steinbusch, Maastricht University, The Netherlands

Pankaj Sharma, University of London, UK

Henry Bakunts, International Medical Centre STROKE, Republic of Armenia

Mira Rakacolli-Kapisyzi, President of Albanian Society of Neurology, Albania

Serhiy Forostyak, Charles University, Czech Republic

The Organizing Committee would like to thank the moderators Dr.Leonardo Pignataro, Columbia University-City University of New york-CSI, USA, Dr.Udai Pandey, University of Pittsburgh Medical Center, USA,Michael Ugrumov, Institute of Development Biology RAS, Russia for their offerings which resulted in smooth functioning of the conference.

The conference was boarded with an opening ceremony followed by a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The best Part of the conference were the keynote forum by prominent scientists, Sergi Ferre, National Institute on Drug Abuse(NID, NIH), USA; Marisela Morales, National Institute on Drug Abuse(NID, NIH), USA; Giuseppe Scalabrino, University of Milan, Italy; Harry W.M. Steinbusch, Maastricht University, The Netherlands; Pankaj Sharma, University of London, UK; Mira Rakacolli-Kapisyzi, President of Albanian Society of Neurology, Albania; Henry Bakunts, International Medical Centre STROKE, Armenia; gave their profitable contributions in the form of highly enlightening presentations and made the conference a best notch one.

Recommended Conferences: Neurology Conferences 2018 | Neuroscience Conferences 2018 | Neurology Conferences | Neuroscience Conferences | Brain Conferences

Magnus Group is prerogative to thank the Organizing Committee Members, Keynote speakers, Chair and Co-chairs on engross the plenary sessions, workshops, and special sessions in an expanded manner to make this conference a privileged Summit.

INBC 2017 Speaker Line Up:

Day 1: Speakers

Michel Baudry, Western University of Health Sciences, USA

Miranda N. Reed, Auburn University, USA

Stephen Wren, University of Oxford, UK

KHIN MAUNG BO, Northern Lincolnshire and Goole NHS Foundation Trust, UK

Mahmoud Kiaei, University of Arkansas for Medical Sciences, United States

Michael Ugrumov, Institute of Developmental Biology RAS, Russian Federation

Kimiko Inoue, Toneyama National Hospital, Japan

Caroline Corbel, Institut de Recherche Dupuy de Lome (IRDL), France

Jong Wook Chang, Samsung Medical Center, Korea

Nicole Hess, University of New England, Australia

Udai Pandey, University of Pittsburgh Medical Center, USA

Gabriele Saretzki, Newcastle University, UK

Shinji Ohara, Matsumoto Medical Center, Japan

Cristine Alves da Costa, Institut de Pharmacologie Molculaire et Cellulaire, France

Leonardo Pignataro, Columbia University-City University of New York-CSI, USA

Sabine Cordes, Lunenfeld-Tanenbaum Research Institute/Mt Sinai Hospital, Canada

Jeffrey Liddell, University of Melbourne, Australia

Niall Finnerty, Maynooth University, Ireland

Debashis Mukhopadhyay, Saha Institute of Nuclear Physics, India

Gilles Guillemin, Macquarie University, Australia

Abigail Takyi, University of Brighton, UK

Day 2: Speakers

Medvedev Svyatoslav, N.P.Bechtereva Institute of the Human Brain of the Russian Academy of Sciences, Russian Federation

Martin L. Pall, Washington State University, USA

Sergio Chieffi, Second University of Naples, Italy

Laura Calza, University of Bologna, Italy

Andrzej Pilc, Polish Academy of Sciences, Poland

Razvana Stanciu, Universite Libre de Bruxelles (ULB), Belgium

Kathryn Commons, Childrens Hospital Boston-Harvard Medical School, USA

Caroline Lucke, Medical Campus University of Oldenburg, Germany

Sabrina Wang, National Yang-Ming University, Taiwan

Marta Nieto, Spanish National Research Council, Spain

Viviane Rostirola Elsner, IPA Methodist University, Brazil

K.L. Leenders, University of Groningen, The Netherlands

Leah K. Light, Brainchild Institute, USA

Kenneth Gaines, Vanderbilt university Medical Center, USA

Bruno Gonzalez, Inserm - U1245 Team NeoVasc, France

Raquel Sofia Marques Neves, Amana Healthcare Medical and Rehabilitation Hospital, UAE

Marina Vladimirovna Zueva, Moscow Helmholtz Research Institute of Eye Diseases, Russia

Laehyun Kim, Korea Institute of Science and Technology, Korea

Prokopenko Semen, Krasnoyarsk State Medical University, Russian Federation

Luyang Tao, Soochow University, China

Anna Bezdeneznykh, Krasnoyarsk State Medical University, Russian Federation

M.R. Graham, Llantarnam Health Care, UK

Serhiy Forostyak, Charles University, Czech Republic

Gladstone C McDowell, Integrated Pain Solutions, USA

Saema Ansar, Lund University, Sweden

Barbara R. Cardoso, University of Sao Paulo, Brazil

Hassan Ravari, Mashhad university of medical sciences, Iran

Day 3: Speakers

Lars Hakan Thorell, Linkoping University, Sweden

Martin Egerth, Lufthansa Aviation Training GmbH, Germany

Munzberg Mathias, BG Klinik Ludwigshafen, Germany

Cecilia Montanez, Centro de Investigacion y de Estudios Avanzados del IPN, Mexico

Moataz Mohamed Talaat Mohamed Kamel El Semary, Cairo university, Egypt

Maria-Magdalena Georgescu, Louisiana State University, USA

Teruna J. Siahaan, The University of Kansas, USA

Toshiki Mizuno, Kyoto Prefectural University of Medicine, Japan

Katherine L Wisner, Northwestern University, USA

Meena Kumari, Kansas State University, USA

Magnus Gram, Lund University, Sweden

Joanna Czarzasta, University of Warmia and Mazury, Poland

Dennis J. Dlugos, University of Pennsylvania School of Medicine, USA

Lynda El-Hassar, Yale School of Medicine, USA

Hoi Ki Kate Lui, Tseung Kwan O Hospital, Hong Kong

Shuhei Yamaguchi, Shimane University, Japan

Victor Vvedensky, Kurchatov Inststute, Russian Federation

Michael Luedtke, Johnson & Johnson, USA

Fatimah Alqarni, King Abdullah bin Abdulaziz University hospital, Saudi Arabia

Bilgehan Atilgan ACAR, Sakarya University Faculty of Medicine, Turkey

Albekov Nurvadi, Chechen State University, Russia

Paul Chapple, Queen Mary University of London, UK

Turkan ACAR, Sakarya University Faculty of Medicine, Turkey

We once again thank all the participants for their wonderful involvement towards the event which helped us for successful execution of this event.

After the successful completion conference, we are exhilarated to announce our next upcoming 2ndEdition of International Conference on Neurology and Brain Disorders (INBC 2018) which is going to be held during June 04-06, 2018 in Rome, Italy.

Mark your calendars for the upcoming spectacular event; we are hoping to see you soon!

Link:
Neurology Conferences 2018 | Neurology Congress 2018 ...

Avera Medical Group Welcomes Neurology Associates

Posted on by

SIOUX FALLS Avera Medical Group announces Neurology Associates, P.C., of Sioux Falls and its physicians will join Avera Medical Group, and the clinic will come under Avera ownership in June.

The physicians of Neurology Associates have been on the medical staff of Avera McKennan Hospital & University Health Center for a number of years, and have served the neurology needs of Avera patients with high quality care, said David Flicek, Chief Administrative Officer for Avera Medical Group. We are proud to welcome them as members of Avera Medical Group. The neurology clinic is located in Plaza 2 on the Avera McKennan campus. The practice also has a Headache Center located at 6709 S. Minnesota Ave.

The name of the practice will change to Avera Medical Group Neurology. The physicians in the practice include Carol Nelson, MD; William Rossing, MD; Todd Zimprich, MD; Lisa Viola, DO; Karen Garnaas, MD; Jeffrey Boyle, MD, PhD; and Warren O.V. Opheim, MD. All are board certified in neurology. Several have advanced subspecialty education in such areas as epilepsy, headache medicine, movement disorders, neuromuscular disease and sleep. They also have special interest in Parkinsons disease, multiple sclerosis, stroke and other conditions that are difficult to diagnose. Together, they comprise the largest neurology practice in South Dakota.

This group of neurologists has been instrumental in the high quality of care delivered through the Avera Brain & Spine Institute, Flicek said. This includes the Stroke Center at Avera McKennan, which is certified as a Primary Stroke Center by the Joint Commission and is nationally recognized for excellence, a specialized neurosciences unit at Avera McKennan, Balance and Dizziness Center, and Autonomic Testing Lab. Now having the neurologists as part of Avera will bring an added measure of comprehensiveness and cohesiveness to our overall neurosciences program, Flicek said.

My colleagues and I have enjoyed close collaboration with Avera over the years, and we have appreciated their support in the development of advanced neuroscience care. We closely identify with the Avera sense of health ministry and mission, and are excited to become part of Avera Medical Group and the wider Avera family, said William Rossing, MD, Neurologist who also serves as director of the Stroke Center at Avera McKennan.

Avera Medical Group Neurology is the largest neurology practice in South Dakota. The 35 employees of Neurology Associates will become employees of Avera. We are looking forward to positioning both Avera and Neurology Associates for the changes that are coming through health care reform, Flicek added.

Follow this link:
Avera Medical Group Welcomes Neurology Associates

Neurologist Dr. Douglas A. Woo joins O’Bleness Hospital staff – Parkersburg News

Posted on by

ATHENS Neurologist Dr. Douglas A. Woo will join the OhioHealth OBleness Hospital medical staff on Wednesday.

Woo is a board-certified neurologist specializing in multiple sclerosis. Additionally, Woo treats the full range of neurology, including dizziness, stroke, seizure, dementia and head/neck pain. He also provides botulinum toxin injections and myofascial trigger point injections to treat selected variants of headaches and neck pain.

Woo received his undergraduate degree from Marquette University and his medical degree from the Medical College of Wisconsin, both in Milwaukee, Wisconsin. He also completed his internship and neurology residency at the Medical College of Wisconsin. He completed a fellowship at the University of Texas Southwestern Medical Center at Dallas focused on the treatment of multiple sclerosis. He is a member of the American Academy of Neurology.

ATHENS - Authorities in Athens County have identified a Meigs County man as the kayaker missing since Saturday ...

A power interruption originally scheduled for Monday has been canceled because of the efforts to restore power ...

PARKERSBURG The Ohio River Valley Water Sanitation Commission has elected Stuart F. Bruny of Logan, Ohio, as ...

PARKERSBURG A familiar face has returned to the Blennerhassett Hotel. Yancy Roush has been hired as the new ...

Read more:
Neurologist Dr. Douglas A. Woo joins O'Bleness Hospital staff - Parkersburg News

What Is Neurology and What Does a Neurologist Do?

Posted on by

Neurology is the medical specialty which focuses on the diagnosis and treatment of diseases and disorders of the brain and nervous system. A physician who practices neurology is called a neurologist. A surgeon who operates on the brain is called a neurosurgeon, which is a surgical specialty rather than a medical specialty.

Neurologists treat stroke patients, as well as patients with traumatic brain injury, epilepsy, Alzheimer's disease, Parkinson's disease, movement disorders, neuromuscular disorders, multiple sclerosis, headaches, and hundreds of other neurological issues, some of which are acute, others of which may be ongoing, or chronic.

Neurology is a field that will have an increasing need for practitioners as an aging population will have more incidence of stroke, Alzheimer's disease, and Parkinson's disease.

A doctor who wishes to become a neurologistfirst attends medical school and graduates with a DO or MD medical degree. Then the doctor would complete a year as an intern in internal medicine and three years of residency in neurology.

Board certification is conducted by the American Board of Psychiatry and Neurology. They provide specialty exams in neurology and neurology with special qualification in child neurology. Subspecialty certifications are available in brain injury medicine, epilepsy, hospice and palliative medicine, neurodevelopmental disabilities, neuromuscular medicine, pain medicine, sleep medicine, and vascular neurology. Certification is dependent on a three-year cycle of maintenance of certification and examinations every 10 years.

Many neurologists work in private practice as part of a specialty group or multispecialty group. But they may also work for hospitals, the military, and managed care organizations.

A patient may be referred to a neurologist for any symptoms that point to the brain or nervous system.

These include seizures, confusion, changes in sensation, muscle and coordination problems, headaches, or after a blow to the head.

The chief diagnostic procedure in neurology is a very thorough history and physical examination. This is where the reflex hammer comes into play. A patient will get a thorough check of the function of all of the cranial nerves, reflexes, and coordination.

The neurologist may order a lumbar puncture to test spinal fluid if the symptoms warrant it. An EEG, CT, MRI, PET scan, or angiography may also be ordered and examined. Neurologists who specialize in sleep medicine may conduct sleep studies. Electromyogram and nerve conduction studies might be done when there is peripheralnervous system symptoms.

Neurological diagnoses can take time and elimination of many rare conditions and disorders. It is one reason that the residency for neurology is specific and three years long. Treatments for neurological diseases may be limited, so reaching a diagnosis does not immediately provide a healing path for the patient.

Neurologists may see a wide range of patients, from a young adult with a brain injury sustained from sports, a fall, or explosive device in a war zone, to an elderly patient showing signs of dementia, or a child with a seizure disorder.

Read the original post:
What Is Neurology and What Does a Neurologist Do?

Genentech’s Ocrevus Offers Stiff Competition to the New High-Efficacy Oral Therapies, Novartis’ Mayzent and EMD Serono’s Mavenclad, While Biogen’s…

Posted on by

EXTON, Pa., March 10, 2020 /PRNewswire/ -- In the last year, the US multiple sclerosis (MS) market saw the introduction of three new disease-modifying therapies (DMTs) for the treatment of relapsing forms of MS (RMS). Fielded between January 21 and February 12, data from 100 neurologists surveyed for the Q1 wave of the ongoing quarterly report series, included in Spherix's RealTime Dynamix: Multiple Sclerosis (US)service, provide insight into the current patterns underlying each of these individual launches.

In March 2019, alongside the approvals of Mayzent and Mavenclad, the FDA revisedthe RMS label for previously approved DMTs to explicitly include clinically isolated syndrome (CIS)1 and active secondary progressive MS (SPMS). The expanded label has had an immediate impact, with neurologists significantly more likely to agree that DMTs approved for RMS would be effective in active SPMS compared to a year ago. While historically among the most commonly switched-to DMTs for active SPMS, this change may also have provided Genentech's Ocrevus with fuel for further uptake, as chronic/advanced disease is now seen a less of a barrier to treat active SPMS patients.

Competitiveness of Novartis' Mayzent with Genentech's Ocrevus for active SPMS appears to be slipping, with fewer active SPMS patients identified as appropriate Mayzent candidates and neurologists more likely to believe that Ocrevus outperforms Mayzent on efficacy in active SPMS compared to nine months ago. Perhaps as a result, Novartis appears to be focusing more on the broad RMS indication and encouraging use in place of Novartis' own Gilenya, the first S1P receptor modulator launched back in 2010.

The reported prescriber base for EMD Serono's Mavenclad has remained flat over the past three months. Neurologists who have yet to prescribe are less likely to believe in Mavenclad's efficacy in reducing the risk of disability progression, favorable risk/benefit profile, and status as a preferred active SPMS option compared to prescribers. In addition, even these early adopters appear less enthusiastic about the breadth of their future Mavenclad uptake, with substantial declines in the estimated percentage of RRMS and active SPMS patients who would be appropriate candidates for the brand over the past three months. EMD Serono will need to prioritize discussions related to appropriate post-Mavenclad maintenance therapy and long-term safety data, while continuing to promote the therapy's unique dosing profile, to compete successfully with Ocrevus.

Trial of Biogen's Vumerity, a next-generation fumarate agent with an improved gastrointestinal tolerability profile compared to Biogen's own Tecfidera, has been swift within the first month of availability with most uptake occurring among RRMS patients switching from Tecfidera. However, remaining nonprescribers may be a tougher sell as they are less likely to believe in the superior tolerability profile or to agree that Vumerity will replace Tecfidera in treatment-nave patients who are candidates for a fumarate agent. As such, almost half plan to wait at least six months before initiating a patient on Vumerity. Reflecting a change from Spherix's Q4 2019 pre-launch assessment, neurologists now estimate a flat fumarate class share over the next six months, highlighting the strong competition within the fumarate class. Patient outreach and education may be a vastly underutilized opportunity for Vumerity, as the majority of patient requests resulted in a prescription and yet only 12% of neurologists have received a Vumerity request within the past three months.

Even with these recent launches of new oral options, the neurologist-reported oral DMT class share has remained flat over the past year, due to stagnant shares of established oral DMTs Gilenya, Tecfidera, and Genzyme's Aubagio. With Gilenya and Tecfidera under pressure from their respective next-generation molecules, neurologists anticipate significant share declines for these brands over the next six months. While Aubagio appears to be immune for now, the Genzyme brand may feel increasing heat with the much-anticipated June 2020 regulatory decisionfor Novartis' ofatumumab, as the subcutaneous anti-CD20 monoclonal antibody was shown to be superior to Aubagio for the treatment of RMS in the Phase III ASCLEPIOS clinical trials.

Along with ofatumumab, two more S1P receptor modulators may be entering the US market within the next nine months Bristol Myers Squibb's Zeposia (ozanimod) with a March 25thPDUFA date and Janssen's ponesimod with a potential decision by the end of 2020. Pre-launch assessment data captured in the current survey suggest that Zeposia uptake patterns will differ from those seen for Mayzent, with a greater opportunity within RRMS compared to active SPMS. However, as the third-to-market S1P receptor modulator, anticipated Zeposia trial rate within the first six months of availability is substantially lower than what Spherix measured at the same time pre-Mayzent launch.

Yet, pre-launch perception does not need to become post-launch reality. A Zeposia label with data on cortical grey matter and thalamic volume loss reduction and delayed cognitive worsening, combined with no first-dose observation requirement and no liver function abnormalities, could help Zeposia become the S1P receptor modulator of choice for the treatment of RRMS. Indeed, one-third of neurologists selected one of these four attributes as the greatest competitive advantage for a new S1P receptor modulator. Assuming an approval later this month and commercial availability soon after, Spherix will track the first 18 months of the Zeposia launch beginning in May, allowing for benchmarking to earlier launches of Vumerity, Mayzent, Mavenclad, and Ocrevus in the MS market.

About RealTime DynamixRealTime Dynamix: Multiple Sclerosis (US)is an independent service providing strategic guidance through rapid and comprehensive quarterly reports, which include market trending, launch tracking, and a fresh infusion of unique content with each wave. The 18th wave of research will publish in June 2020.

About Spherix Global InsightsSpherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select immunology, nephrology, and neurology markets.

All company, brand or product names in this document are trademarks of their respective holders.

For more information contact:Virginia Schobel, Neurology Franchise HeadEmail:info@spherixglobalinsights.comwww.spherixglobalinsights.com

Reference:

1. Genzyme's Lemtrada and EMD Serono's Mavenclad, generally recommended for use after one or more previous failure, did not have the CIS indication added in their RMS label.

View original content to download multimedia:http://www.prnewswire.com/news-releases/genentechs-ocrevus-offers-stiff-competition-to-the-new-high-efficacy-oral-therapies-novartis-mayzent-and-emd-seronos-mavenclad-while-biogens-vumerity-begins-to-chip-away-at-the-companys-own-tecfidera-301020893.html

SOURCE Spherix Global Insights

Excerpt from:
Genentech's Ocrevus Offers Stiff Competition to the New High-Efficacy Oral Therapies, Novartis' Mayzent and EMD Serono's Mavenclad, While Biogen's...

Abnormal Cerebral Blood Flow May Influence the Etiology of Parkinson Disease – Neurology Advisor

Posted on by

Patients with Parkinson disease (PD) tend to have an increase in iron content with reduced perfusion in the substantia nigra, as well as structural abnormalities and reduced flow in the left dural sinuses, according to study results published in Parkinsonism and Related Disorders.

Although limited data are available on the microvasculature of the brain in PD, several studies have reported that abnormal flow to the substantia nigra pars compacta could play a role in the pathogenesis of PD. The goal of the current study was to explore the vascular abnormalities, flow, and increases in midbrain iron content, a hallmark of the disease, in patients with PD.

The study cohort included 85 patients (45 women; mean age, 58.79.6 years) with PD from the neurology department of the First Affiliated Hospital of Zhengzhou University, Henan, China, and a similar number of age- and sex-matched control individuals (44 women; 60.29.9 years) from the province of Henan.

All participants were scanned with 3T MAGNETOM Prisma scanners, and the researchers assessed vascular abnormalities, using magnetic resonance venography; average cerebral blood flow, using 2-dimensional flow quantification; and substantia nigra iron content using susceptibility mapping. The patients with PD and healthy control individuals were divided into 4 vascular categories according to the presence or absence of dural sinuses and their flow characteristics.

The researchers reported that in patients with PD, there were abnormalities in flow, perfusion, and dural sinus structural characteristics. Venous structural and functional abnormalities in the 2 most severe categories were evident in 42% of patients with PD, whereas only 14% of the controls showed these abnormalities. Total arterial flow (normal range varies from 10 to 20 mL/s) was significantly lower for the PD group (10.91.8 mL/s) compared with for healthy control individuals (11.62.1 mL/s; P =.02).

Little flow on the left side was evident in 53% of the patients with PD compared with 14% of the healthy control individuals. Patients with PD also had higher heart rates (mean 7516 vs 679 beats per minute for the patients with PD and control individuals, respectively) and lower perfusion (489 vs 518 mL/100 g per minute, respectively). The lower perfusion correlated with increased iron content in the substantia nigra.

The study had several limitations, according to the researchers, including no data on local perfusion in the midbrain; limitations secondary to 2-dimensional, instead of 3-dimensional, flow analysis; and possible effect of various factors on venous shape and morphology.

These results suggest that abnormal flow could play a role in the etiology of PD, advancing our understanding of this debilitating disease, conclude the researchers.

Reference

Zhang C, Wu B, Wang X, et al. Vascular, flow and perfusion abnormalities in Parkinsons disease. Parkinsonism Relat Disord. 2020;73:8-13.

View original post here:
Abnormal Cerebral Blood Flow May Influence the Etiology of Parkinson Disease - Neurology Advisor

Edited Transcript of 4523.T earnings conference call or presentation 31-Jan-20 7:30am GMT – Yahoo Finance

Posted on by

Tokyo Feb 1, 2020 (Thomson StreetEvents) -- Edited Transcript of Eisai Co Ltd earnings conference call or presentation Friday, January 31, 2020 at 7:30:00am GMT

Eisai Co., Ltd. - Senior VP & President of Neurology Business Group

Eisai Co., Ltd. - Executive VP, CFO & Chief IR Officer

Eisai Co., Ltd. - VP and Chief Medicine Creation Officer & Chief Discovery Officer of Oncology Business Group

Eisai Co., Ltd. - Senior VP & President of Oncology Business Group

Daiwa Securities Co. Ltd., Research Division - Research Analyst

Nomura Securities Co. Ltd., Research Division - Senior Analyst

Mitsubishi UFJ Morgan Stanley Securities Co., Ltd., Research Division - Senior Analyst

Thank you very much for taking your time to attend the financial results presentation session by Eisai on the third quarter fiscal 2019.

Before we begin, there are some housekeeping announcements. Please make sure that you have the distributed materials in front of you. There should be a deck of slide that will be used in the presentation and flash report and related materials. If any of the document is missing, please raise your hand.

Then I would like to introduce the speakers today, Executive Vice President, CFO, Chief IR, Mr. Ryohei Yanagi; Senior Vice President and President of Neurology Business Group, Mr. Ivan Cheung; and Senior Vice President and President of Oncology Business Group, Mr. Terushige Iike.

Today's presentation will be made by Mr. Yanagi to cover the first part, which is financial part, and the latter part, operation part, will be presented by Mr. Cheung and Mr. Iike.

Ryohei Yanagi, Eisai Co., Ltd. - Executive VP, CFO & Chief IR Officer [2]

Now I would like to report it to you. On the part, covering the financials. Here is the Q3 9 months cumulative consolidated statement of income.

Revenue, top line, was JPY 486.1 billion, up 4% year-on-year. All global brands grew 44% from a year earlier. Growth driver, LENVIMA could reach the revenue of JPY 80.5 billion, increased by JPY 37.2 billion, 1.9x as much as last year, so almost doubled. And rapid growth of LENVIMA for a transfer of generic business, brought about the improvement of product mix, and cost ratio has improved or lowered to 26.2%.

As a result, gross profit was JPY 358.9 billion, up 10%, up from a year earlier. The double-digit growth was achieved, within the increased ratio of the gross profit. Within this increased ratio, the total cost increase ratio was controlled and financial discipline worked well, and OP grew about 30%.

And let me share with you the breakdown of expenses. R&D expenses were JPY 103 billion, which seems on the flat from a year earlier. But including partners reimbursement, actual R&D -- total R&D expenses were JPY 151.8 billion, 14% increase from year earlier. And this -- these expenses account for over 31% of revenue.

Among the top-tier Global 25 companies, we can say that we have been one of the most proactively investing company in R&D in the world. And SG&A expenses were JPY 188.4 billion, 12% increase and -- from a year earlier and SG&A expenses have account for 38.8% of revenue. Difference from a year earlier, the JPY 20 billion increase was mostly due to the payment to -- but due to the profit sharing related to LENVIMA. Therefore, given the robust growth in LENVIMA, a positive spending was made. Such cost of profit sharing with the Merck, excluding that impact, SG&A expenses were almost flat, and they accounting for 31% of revenue. And there is no much deviation from the median of global peer companies.

Operating profit was JPY 73.3 billion, up 30% from a year earlier. OP margin has exceeded a 15% mark.

During the third quarter, noteworthy things were the reversal of provisions on income taxes in the U.S., and there was increase in income taxes of the company following the repayment of trading capital from U.S. subs to the company to resolve the group's cash imbalance. Therefore, tax position improved significantly.

Bottom line profit for the period attributable to owners of the parent reached JPY 73.3 billion, 83% increase from a year earlier, a significant increase, and a 9 months cumulative reference value for ROE exceeded 15%, reaching global standard.

Looking at the balance sheet items. For this fiscal year, which we regard as a proactive investment year, and we are increasing the dividend by JPY 10 to JPY 160 per share for full year dividend. And the -- a little less than JPY 30 billion was expensed for capital investment in the past. But this fiscal year, we are doubling up to JPY 60 billion in CapEx, proactive investment is being made into ICT or ventures or a PP&E.

Therefore, net cash has slightly decreased, but net DER is minus 0.22. Therefore, net -- very significant net cash position is maintained, and the capital ratio is exceeding 61%. The debt free status is maintained. Therefore, we do not have any concerns on the financial strength. Therefore, we are achieving those proactive investment and dividend payments.

Next, here is a breakdown of revenue migration. Last year, 9 months cumulative revenue was JPY 467.3 billion. And given the growth of 4 global brands, Japan, China, Asia business is through the revenue and LENVIMA associated milestone payments was JPY 225 million last year, but it has reduced to JPY 150 million this year. But we are expecting to reduce significant milestone payment in the fourth quarter. Transfer of shares of Elmed Eisai and due to other factors in the business development related factors, revenue increased by JPY 18.8 billion year-on-year to reach JPY 486.1 billion.

Next, please.

On this slide, you can see the breakdown of operating profit migration and this waterfall chart. And last year, OP was recorded at the JPY 57.1 billion, in parallel to the movements in revenue due to growth 4 global brands, Japan, China, Asia, we could record the steady growth in OP. And as I said earlier, milestone payments related to LENVIMA were slightly decreased, but we expecting to receive significant milestones in the fourth quarter. Due to the proactive spending, the increase of the shared profit paid by Eisai to Merck related to LENVIMA was JPY 20 billion, and R&D expenses were almost flat. And inclusive of the impact by BD-related factors and -- OP increased by JPY 16.2 billion year-on-year to reach JPY 73.3 billion.

R&D expenses may have seemed to be almost flat from a year earlier, but inclusive of the reimbursement from partners in the amount of JPY 48.7 billion. Therefore, actual spending was JPY 151.8 billion. Therefore, a double-digit growth was observed in the R&D expenses.

Towards the future, we are making the proactive investment in R&D, while we are -- we have achieving the 30% significant increase in OP. And I think this is the benefit of the partnership model.

On this slide, we are providing you with a full year forecast for earnings. Revenue will be JPY 680 billion. Operating profit will be JPY 110 billion. These have remained unchanged from the last announcement. As I said earlier, due to the improvement in tax position, the lines from profit for the year below have been revised upward. And the profit targets set for 2020 have been already -- will be achieved year earlier.

And in FY 2006, the profit for the year is going to record -- put a record high profit, exceeding the record in 2006, and ROE will exceed 15%; and DOE, 7%; and ROE, 15%, which is set under EWAY 2025 for 2025 will be achieved.

As I said earlier, with strong balance sheet, DOE will be regarded as KPI, and the dividend per share will be maintained at this JPY 160. We do not have any concern about that. Through these, we are trying to maximize enterprise value. We have -- I have covered the financial section, and as the source of the profit and revenue, operations will be covered by a responsible persons of oncology -- neurology and oncology after me.

--------------------------------------------------------------------------------

Ivan Cheung, Eisai Co., Ltd. - Senior VP & President of Neurology Business Group [3]

--------------------------------------------------------------------------------

Today, I would like to cover neurology product development status for the third quarter.

First of all, I would like to talk about aducanumab and BAN2401, and I'd like to give you the update on the development for aducanumab. Currently, Biogen is actively engaging with the FDA as well as regulators in Europe and Japan. And In order to complete regulatory filing in the U.S. as soon as possible, we are working with Biogen in preparation, and the protocol has been already filed with FDA for aducanumab. And we are coordinating and cooperating with Biogen.

On the other hand, for BAN2401 through collaboration with ACTC, AD prevention study is being planned. This study was named AHEAD 3-45. In this study, its real clearance of protofibril in participants -- in clinically normal participants, we are planning to study and evaluate the prevention of progression of brain pathophysiology.

Phase III cohort will include cognitively normal participants with intermediate levels of amyloid as determined by amyloid PET scan. And the A45 cohort will include participants with little to no cognitive impairment who have elevated levels of amyloid in the brain. These 2 cohorts will be enrolled in 1 single study, in this Phase III study. And we have already signed a contract with ACTC and targeting amyloid how neurodegeneration or biomarker panels by ATN will be used as endpoints, and we plan to initiate this Phase III study in this year, 2020. And Phase III study, Clarity AD, which is currently ongoing, targeting patients with early AD, which is ongoing steadily, in Japan, the U.S., EU and Asia. And by this year, we plan to complete patient enrollment, final readout of primary endpoint is targeted in the first quarter in fiscal year 2022.

In addition to these studies, Phase II open-label extension study will be conducted on the same patient population of the Phase II Study 201, given the positive results of the Study 201, open-label extension study has been already started for evaluating long-term safety and efficacy.

Next, here is the BAN2401 Study 201-OLE, the baseline data was published in CTAD in December last year. After the completion of the treatment with BAN2401, brain amyloid reduction at the end of core persists after BAN2401 discontinuation for amyloid PET SUVr. This chart shows the changes after the average of 2 years of treatment in Study 201.

Emulated reduction was founded to be almost maintained for about to 2 years on the average after discontinuation of BAN2401, and a treatment difference for clinical outcomes at the end of core appears to be maintained following BAN2401 discontinuation.

Given this data, but just BAN2401's potential disease-modifying effects.

Next, about new insomnia treatment, DAYVIGO, is what I'd like to explain. DAYVIGO is in-house discovered and developed dual orexin receptor antagonist. Last year, in December, in the United States, it was approved for treatment of insomnia, and in Japan, in January, approval was obtained.

DAYVIGO exhibits both OX1R, OX2R orexin receptors, thereby, alleviate excessive awake condition. And especially, it is involved in -- it has stronger inhibition effect in orexin 2 receptor, which is involved in suppression of no REM sleep.

There are 2 Phase III studies, SUNRISE 2 and SUNRISE 1. And insomnia -- correction, sleep onset and sleep maintenance were demonstrated with statistical significance. And in SUNRISE 2, long-term efficacy and safety were observed.

Sleep well, wake well, be well, will be realized by DAYVIGO, and there is no rebound insomnia, and for chronic insomnia, long-term treatment is possible. For insomnia patients, we aim to contribute to such patients with sleep disorder by improving their symptoms.

In the United States, we plan to launch following scheduling by the U.S. DEA. And in Japan, we plan to launch in the first quarter of fiscal 2020. There are social issues caused by insomnia disorder. Approximately 30% of adults worldwide have symptoms of insomnia, and up to 10% are diagnosed as insomnia, approximately 10 million in U.S. and approximately 4.5 million in Japan are receiving treatment for insomnia.

Poor sleep is associated with a wide range of health consequences, including hypertension, accidental injury, diabetes, obesity, depression, heart attack, stroke and dementia.

Disease risks may be elevated by poor sleep. Due to difficulty falling asleep and staying asleep, patients may suffer from fatigue, difficulty concentrating and irritability, and productivity may decline as a result. DAYVIGO seeks to decrease negative impact on society caused by sleep disorder to fulfill patients' unmet needs.

Turning to Fycompa next. In this -- in the past quarter, we were able to make progress in value maximization for patients. In China, in December 2019, for adjunctive treatment of partial onset seizure, we were able to launch Fycompa. Fycompa was designated for Priority Review. And after submission within 12 months, we were able to obtain approval. In Japan, in January this year, approval was given for additional indications -- the following 3 additional indications: monotherapy for partial onset seizures, pediatric use in partial onset seizures, new formulation of fine granules at the same time. In EU pediatric use in partial onset seizures is under review and LGS Global 3 study is steadily ongoing.

As for IV formulation, in the United States and in Japan, we aim to submit in early fiscal 2020, and and in EU within fiscal 2020. So with Fycompa, we are expanding launch countries and receiving approvals of new indications and new formations. And this provides new treatment options to patients with epilepsy.

This is my last slide. In neurology area, this is the development pipeline. After October last year, we were able to launch 2 products and obtain 5 approvals and initiate 1 Phase I study. And our neurology portfolio is steadily growing.

As you can see, as a pharmaceutical company, we are addressing because of AD amyloid tau in neurodegeneration, all of ATN as the only company to do so. We are approaching ATN, and we have a pipeline of disease-modifying drug that approaches ATN. Regarding tau, we have E2814 new anti-tau antibody, and we were able to initiate Phase I study. In AD, there are differences with other tau related disease. There is highly toxic MTBR, which tend to be aggregated in the brain, and MTBR or microtubule binding region fragments are increasing with reduced this characteristic. And MTBR fragments are certainly causing tau degeneration propagation by accumulating in brain.

And unlike other anti-tau antibody, E2814 can target MTBR fragments and maybe able to exhibit a strong disease-modifying effect according to our understanding. The achievements in neurology area in the third quarter was presented in my presentation. Thank you.

--------------------------------------------------------------------------------

Terushige Iike, Eisai Co., Ltd. - Senior VP & President of Oncology Business Group [4]

--------------------------------------------------------------------------------

Next, I would like to report on our progress in oncology area. In the beginning, as my colleague, Mr. Yanagi mentioned, LENVIMA achieved JPY 80.5 billion sales cumulatively over 3 quarters. This is a growth of 86% over the previous year, same period, which is a strong growth.

Americas were boosted by HCC, and last September, approval was obtained for endometrial carcinoma, which is an indication for -- endometrial carcinoma, which exacerbated for systemic therapy and the LENVIMA was the first drug in the United States to receive indication for this. And it is expanding smoothly, and in China, in Japan as well, HCC-led our sales.

In HCC, tumor size may be large or tumor number maybe too many, and local therapy may not be suitable for such patients. LENVIMA can be given to shrink tumors. And then curative local therapy, including TACE may be applied, and this is called conversion therapy. Already in Japan, about 60 patients are undergoing this conversion therapy.

As for EMEA, Germany is showing the fastest growth. And in Russia, LENVIMA was listed in the national guideline and is also growing at the pace similar to Italy and France. For this fiscal year, LENVIMA sales is expected to exceed $1 billion.

This month in the Journal of Clinical Oncology, Phase I/II study results of combination between LENVIMA and KEYTRUDA were published. There are 6 types of cancer that were targeted for the study. As shown in this waterfall block, there is tumor a shrinkage observed, and safety profile is showing that the safety is manageable. In case of RCC, tumor shrinkage or overall response is 70% and duration of response is 20 months, and therefore, good results are obtained. And patients who die from cancer are most of the patients die from lung cancer, and NSCLC accounts for majority of the lung cancer, ORRs 33%, DOR was 11 months.

We do not (inaudible) based on previous therapy in these studies. Most of the patients who participated in the study may have received the immuno checkpoint the drug, including KEYTRUDA. Despite that, ORR and DOR as high as these were achieved. In multiple types of cancer, a combination of LENVIMA and KEYTRUDA, cancer was -- cancer back bone therapy, that is our belief, and we are carrying out studies for submission. Pivotal studies are underway. This is the development of combination therapy with KEYTRUDA, but in neck cancer first-line study included 12 studies have been initiated. One study that is remaining, which is second line for head and neck cancer, is under preparation. And 2 days ago, clinical trial disclosure was made so we were not able to include that in this slide. There is one more trial that is added, that is for HCC in combination with TACE. This TACE is transcatheter chemoarterial embolization (sic)

[transarterial chemoembolization] and in combination with LENVIMA, KEYTRUDA, TACE, the study will be carried out. And this was not included initially in our contract with Merck. But in HCC, there is an outstanding usefulness observed in combination therapy. And last year, after consultation with the Merck, the 2 parties decided to start this study. And 6 types of cancers are covered by LEAP-005 in basket-study style, triple-negative breast cancer, gastric cancer, included 6 sites of cancer are included. The ASCO, the other day -- Japanese doctors announced the results of 69% of ORR for gastric cancer for combination therapy with KEYTRUDA, and LEAP-005, in which Japanese doctors announced investor-initiated trial results, and we will be getting results from LEAP-005 as well.

So about next steps, we would like to consult with our partner Merck.

Turning to China, which is our important region. For HCC indication, JPY 10.7 billion revenue was accumulated in Q3 fiscal 2019, exceeding revenue in Japan and EMEA. Through collaboration with MSD, we are expanding contribution to patients, mainly in city areas by increasing commercial resources and by increasing coverage, and in regions and to small and medium-sized hospitals, through utilization of e-marketing, we would like to expand patient access.

As for thyroid cancer -- differentiated thyroid cancer, global Phase III is already completed. And based on the results, submission was accepted by the authority. As for the thyroid cancer incident in China, approximately 190,000 new cases are diagnosed. And that number in Japan is 20,000. So in China, it is almost a tenfold. And there is a strong unmet medical need. And we are making utmost efforts in our response to the review process by the authority.

For Halaven, this is Eisai in-house developed compound. And in January the 12, we had a launch event. After launch in December 2019, approximately 370,000 new cases of breast cancer are diagnosed in Japan. So this is about 5x that in Japan. And a Fareston hormonal therapy for breast cancer has been launched in China since 9 years ago. Using that base, we would like to build for Halaven to Chinese patients.

Next, E7090 fibroblast growth factor receptor inhibitor. FGFR 1, 2, 3 selective inhibitor is E7090. At Tsukuba Research Laboratories, using LENVIMA discovery know-how and compound library, E7090 was discovered and developed. Phase I expansion part result was published at ASCO-GI the other day. FGFR2 mutation biliary tract cancer or gastric patients -- gastric cancer patients are included in this expansion plan. And those was 140-milligram in the earlier dose escalation part. Higher dose was considered, however, biomarkers suggest that sufficient efficacy is obtained at 140 milligram and that is why this dose was selected. Red bars are biliary tract cancer. Out of 6 of 5 are tumor shrinkage and 1 had stable disease, so strong efficacy was observed.

Blue is gastric cancer. Perhaps other than FGFR2, other factors may be contributing to proliferation of cancer. There seems to be cancer heterogeneity in gastric cancer, more so than in biliary tract cancer.

FGFR2 fusion, biliary retract cancer, on this, we received SAKIGAKE designation from MHLW last year. In consultation with the authority, we have decided to conduct a joint Phase II study, jointly between Japan and China, and this has already been started. In the 3 months, we were able to launch one product and one submission and initiation of one Phase III, one Phase II and one Phase I studies in oncology, E7766 STING agonist.

This is a Phase I study. Two Phase I studies will be run in parallel, and one is injection in the tumor and the other is injection in bladder for bladder cancer patients. And breast cancer in HCC pipelines are also making progress for early development products, and combination with KEYTRUDA in LEAP study series, we expect results of one after another from LEAP studies this year and next year for these types of cancer so that they can serve -- so that the therapy can serve as a backbone therapy, we would like to work together with Merck. That concludes the oncology presentation part.

Then I would like to summarize at the end. Today, the three speakers have presented. Eisai's operations and financials are currently very robust and making strong advances. EWAY 2025 vision is medical societal innovator. For example, as explained today, next-generation AD treatment is medical innovation. And that is based on ecosystem, which is quite inclusive, and this can turn into a massive social innovation, and we are making steady progress in implementing such a business model. And as a result, EWAY 2025, at the time of 2025, ROE of 15% level should be achieved in stable fashion and that probability of success is being enhanced. Furthermore, over extremely long term, beyond 2025 -- even beyond 2025, there should be contribution to enterprise value due to a rich pipeline filled with next-generation product candidates and progress is made.

At Eisai, long-term sustainable growth of enterprise value is pursued. And amongst stakeholders, we hope that we continue to receive your support.

With that, I would like to conclude. Thank you very much.

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Unidentified Company Representative, [1]

--------------------------------------------------------------------------------

Next, we would like to open the floor for questions. First, we would like to entertain questions in this room before receiving questions from participants over the phone. If you have questions, please do use the microphone, and please give us your name and affiliation before your question. If you have questions, please raise your hand.

--------------------------------------------------------------------------------

Motoya Kohtani, Nomura Securities Co. Ltd., Research Division - Senior Analyst [2]

--------------------------------------------------------------------------------

My name is Kohtani. I am from Nomura Securities. I have three questions about oncology. First, ASCO-GI, as you said that IIS EPOCH 1706 and 29 patients included. Therefore, 69% was the response rate and that the sample size were very small, but although -- but it was not a coincidence. And with the monotherapy KEYTRUDA, the response was 15%. And then with the chemotherapy -- and then only 45% -- with the chemotherapy, 40%. And with the chemotherapy 45% -- 5% was the response rate. Please let me know.

LENVIMA monotherapy in gastric cancer, what kind of data was published? Are there any such data and VEGF and PD-L1 antibodies? And do you think that there has been a powerful synergy with PD-L1 antibodies like the KEYTRUDA?

Probably, it will be difficult to file solely based on this study data. But I think you mentioned earlier, this is with Merck, LEAP or we did include it in the basket trial being conducted with Merck is adding such a study. And then how this addition will -- may have an impact on your clinical development?

--------------------------------------------------------------------------------

Unidentified Company Representative, [3]

--------------------------------------------------------------------------------

Thank you for your question. Dr. Owa, who is in charge of science of oncology. Dr. Owa is going to respond to questions.

--------------------------------------------------------------------------------

Takashi Owa, Eisai Co., Ltd. - VP and Chief Medicine Creation Officer & Chief Discovery Officer of Oncology Business Group [4]

--------------------------------------------------------------------------------

Thank you very much, Mr. Kohtani. Regarding your first point, LENVIMA monotherapy data for gastric cancer. What kind of data do we have for LENVIMA monotherapy , for example, with 20 or 30 patients with gastric cancer, we do not have any data for monotherapy. But so far, Phase I study were conducted for LENVIMA and that there were gastric cancer patients involved. And for -- even for monotherapy, there were partial response. That data is available, but there is nothing taken from this data because the sample size was not large enough.

--------------------------------------------------------------------------------

Motoya Kohtani, Nomura Securities Co. Ltd., Research Division - Senior Analyst [5]

--------------------------------------------------------------------------------

And so how should we interpret this data?

--------------------------------------------------------------------------------

Original post:
Edited Transcript of 4523.T earnings conference call or presentation 31-Jan-20 7:30am GMT - Yahoo Finance

Study Finds Suicide Rate Higher Among Those With Neurological Disorders – Everyday Health

Posted on by

People with neurological conditions like Parkinsons disease, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS, also known as Lou Gehrigs disease), Huntingtons disease, and dementia are at higher risk for suicide, a study published in February 2020 in the Journal of the American Medical Association has found.

According to the authors, from the Danish Research Institute for Suicide Prevention (DRISP) in Copenhagen, the higher rates of suicide among those with these brain disorders are likely the result of stress and feelings of hopelessness when they learn their diagnosis and prognosis. Although the symptoms of most of these conditions can be managed with drug treatments and other approaches, none can be cured at least not yet.

In addition, many of these disorders lead to significant disability, which may impact the quality of life of those who are diagnosed as well as their families and friends.

Distress at the time of diagnosis plays a role, for instance, for people with dementia, explains study coauthor Annette Erlangsen, PhD, who heads the research program at DRISP. For severe disorders, such as Huntingtons and ALS, the risk of suicide might be related to the course of the disorder.

Some of these disorders, perhaps as a result, are also linked with a higher risk of mood disorders like depression and anxiety, which may lead to thoughts of suicide, she adds.

To assess the risk of suicide among people with certain neurological disorders, Dr. Erlangsen and her colleagues reviewed the health records of more than 7.3 million people in Denmark from 1980 through 2016. All of the people included in the analysis were 15 years of age or older as of 1980, and approximately 1.25 million of them had received medical treatment for a head injury, stroke, epilepsy, polyneuropathy, diseases of myoneural junction (in which signals from nerves to muscles are disrupted, leading to muscle weakness and fatigue), Parkinsons, MS, central nervous system infections, meningitis, encephalitis, ALS, Huntingtons, dementia, intellectual disability, and other brain-related conditions during the study period.

Ultimately, more than 35,000 of those included in the analysis died by suicide, and nearly 15 percent of those who died by suicide had been diagnosed with a neurological disorder. Overall, Erlangsens team found that those with neurological disorders are almost twice as likely to take their own lives as those who hadnt been diagnosed with these conditions.

Risk of suicide among those with ALS was almost 5 times higher than that of the general population, while the suicide risk for those with Huntingtons, MS, and epilepsy was roughly twice as high.

The researchers also found that the risk of suicide rose as the number of hospital visits rose.

RELATED: What Your Doctor Wont Tell You About Epilepsy: It Can Kill You

Based on their findings, the authors suggest that caregivers friends and loved ones as well as healthcare professionals closely monitor those with these conditions for depression and anxiety, emotional distress, and suicidal thoughts.

Its important to emphasize that suicide is a rare event in general and also among people with neurological disorders, Erlangsen says. However, she adds, Its surely important to be aware of ones mental well-being especially when diagnosed with a chronic disorder. Luckily, its few who develop depressive symptoms, but if one does, then it is important to speak to a healthcare professional and assess whether further initiatives are needed.

More here:
Study Finds Suicide Rate Higher Among Those With Neurological Disorders - Everyday Health

Neurologist treated thousands of Santa Feans | Local News – Santa Fe New Mexican

Posted on by

Dr. Michael Baten wanted to help people who were hurting ever since he was 13 and saw the painful effects a stroke had on his mother.

Some 60-plus years later, he had become so well known for practicing medicine in Santa Fe that people would joke, If you are not seeing Dr. Baten, then you have a family member or friend who is.

The longtime Santa Fe neurologist and sleep medicine expert died Saturday in Albuquerque from a neurological illness that overcame him late last year, relatives and friends said. He had turned 75 in February.

Its no wonder he wanted to become a neurosurgeon, said ex-wife Caroline Crosby , referring to the impact his mothers stroke had on Baten. The hospital was his family.

Baten was born in Paterson, N.J., in February 1945. An only child, he developed an early interest in classical music and dressing well.

Following high school, Baten studied medicine at the University of Pennsylvania and then at Duke Universitys School of Medicine. After medical residencies in Virginia and New York City, he moved to New Mexico in the late 1970s with an eye toward opening his own practice.

Crosby and other friends said Baten took over a neurological practice run by another physician before later branching into sleep medicine.

He was always studying, always learning, always trying to become a better doctor, said his cousin Joan Ehrlich.

He would wake up at 4 or 5 a.m. to read medical journals, she recalled. He was so serious about this work that he read constantly. Anytime we were someplace together, I would always find him sitting off somewhere studying.

Batens knowledge of classical music would amaze people when, upon hearing a piece on the radio, he would identify not only the composer and title but the orchestra or symphony.

He could tell whether it was the London Philharmonic Orchestra or the Philadelphia Orchestra playing it, said Crosby, who also worked in her ex-husbands office for a time.

She recalled when he had at least 35,000 patient medical files and thats half of Santa Fe.

An avid bicyclist, skier and triathlete, he also developed an impeccable taste for dressing stylishly, Crosby and Ehrlich said.

He looked like he just stepped off the cover of GQ magazine, Crosby said. They say his mother, Edna, always looked like a movie star. I think Michael inherited her sense of fashion.

Rabbi Neil Amswych of Temple Beth Shalom shared stories in an email from those who praised Baten for his generous spirit and dedication to his profession.

In the early 90s, he went into St. Vincent Hospital [now Christus St. Vincent Regional Medical Center] to see a homeless man who had been having seizures in the arroyo, Amswych said. Michael gowned up with the nurses and bathed the man.

He loved his early days in Santa Fe, when the staff from the hospital would hold gurney races around the Plaza.

Baten is survived by his two children with Crosby Rachel Baten, 16, and Alex Baten, 19, and by several cousins.

Amsywch and Crosby said a memorial service for Baten is scheduled for 11 a.m. Tuesday at Temple Beth Shalom, 205 E. Barcelona Road.

View original post here:
Neurologist treated thousands of Santa Feans | Local News - Santa Fe New Mexican

Feng leads research on motor recovery therapy – Duke Department of Neurology

Posted on by

Non-invasive transcranial direct current stimulation has significant potential to contribute to the otherwise sparse landscape of stroke recovery therapies for post-stroke limb weakness, according to Wuwei Wayne Feng,MD, MS, the new chief of the Stroke and Vascular Neurology Division in the Department of Neurology.

Treatment for stroke rehabilitation and recovery is quite lacking, as there is not much well-established evidence in the field, says Feng, who also serves as medical director of Dukes Comprehensive Stroke Center. We want to particularly focus on brain modulation techniques and hope to bring more research to this much-needed area to come up with new ways to zap the brain and develop new therapies for patients.

To further these efforts, Duke soon will become the 13th stroke center in the United States to participate in a four-year phase II multicenter transcranial direct current stimulation study funded by an $8.1 million grant from StrokeNet, a National Institutes for Health program. The TRANScranial Direct Current Stimulation forPOst-stroke MotorRecovery: A phase II sTudy (TRANSPORT 2) will evaluate three dosing selection based on the preliminary efficacy, safety, tolerability, and feasibility for participants who have experienced a first-ever ischemic stroke within one to six months of enrolling in the study.

During the study, patients will receive direct current to the scalp through two electrode pads for 30 minutes per day while simultaneously receiving modified constraint-induced movement therapy for two hours per day. The three dosing groups are sham, 2 milliamps, and 4 milliamps, and patients will return to Duke for 10 total intervention sessions over a two-week period.

If we can select the optimal dose group from this study and confirm the effectiveness in the phase III study, this will become a new rehabilitation therapy for stroke patients with motor deficitsthe most common complication after stroke, he says.

(This article originally appeared on Clinical Practice Today, a free magazine and website geared for clinicians. Read it and other articles here.)

Feng explains the benefit of this combination of therapies: On the central nervous system/brain level, patients receive positive current on the affected side to boost brain activity and negative current on the unaffected side to suppress brain activity. On the peripheral nervous system/limb level, patients suppress the movement of the unaffected hand by wearing a large mitten while receiving high-intensity therapy to force the use of the hand affected by stroke. In this way, patients get double stimulation to trigger the brain to rewire itself to function better, Feng adds.

As part of the TRANSPORT 2 study, Feng has developed an imaging biomarker that helps determine the exact location and severity of damage to the corticospinal tractthe pathway that connects the brain to the limbin patients who have experienced ischemic stroke.

We use a combination of imaging biomarkers developed by my lab, a neurophysiology tool, and clinical assessment to carefully calculate the exact brain damage from the stroke, Feng says. This approach will help identify what kind of patients will best respond to this type of brain stimulation intervention.

In addition to leading this national study, Feng and his team in the brain modulation and stroke recovery lab will focus on the study of other non-invasive neuromodulation tools in stroke recovery, including transcranial magnetic stimulation, low-intensity focused ultrasound, and a remote-ischemic preconditioning tool that Duke researchers will study patients to develop future innovative techniques for stroke recovery.

Patients can enroll in the TRANSPORT 2 study or the various other stroke rehabilitation studies at Dukes brain modulation and stroke recovery lab by contacting Kristina Balderson at kristina.balderson@duke.edu or 919-684-0071.

Follow this link:
Feng leads research on motor recovery therapy - Duke Department of Neurology

Results of US Evoke pivotal study published in The Lancet Neurology – NeuroNews International

Posted on by

Saluda Medical has announced The Lancet Neurology journal published results from the US pivotal study demonstrating its Evoke ECAP-controlled, closed-loop spinal cord stimulation (SCS) system provided long-term, statistically superior, and clinically meaningful pain relief for patients with chronic intractable back and leg pain out to 12 months compared to open-loop SCS.

The results generated in the US Evoke pivotal study demonstrate that the spinal cord response to stimulation can be successfully measured and used to adjust stimulation to maintain spinal cord activation within the patient-specific therapeutic window. The study establishes that the controlled level of spinal cord activation provided by closed-loop technology is associated with increased pain relief and positive clinical outcomes.

Evoke is the first closed-loop SCS system that measures the spinal cords response to stimulation (via ECAPs, or evoked compound action potentials) and adjusts on every pulse to optimize activation within the patients therapeutic window.

Nagy Mekhail, professor at the Cleveland Clinic Lerner College of Medicine, director of Evidence-Based Pain Medicine Research and Education in the Department of Pain Management at the Cleveland Clinic, and the first author of the publication, commented, This study provides robust evidence of outcomes in the treatment of overall pain, with superior patient responder rates with closed-loop SCS compared to the open-loop SCS control group.

Beyond the clinical results, this study has important practical implications as it establishes that individual-specific therapeutic windows can be identified and targeted to maintain spinal cord activation at therapeutic levels and improve care long term. In fixed-output and open-loop SCS systems, the amount of energy reaching the spinal cord continually fluctuates, faster than a patient can adjust with a remote, resulting in less time within the therapeutic window.

Essentially, Evoke is designed to listen to the spinal cord, compare the spinal cord response to the target level chosen by the patient, and adjust stimulation in real-time to provide the optimum dose. We believe this is the first step for the field of neuromodulation to move toward an interactive, mechanism-based, individualised therapy founded on an objective outcome measure. This represents a significant opportunity to improve the success of neuromodulation for patients seeking chronic pain relief.

Lawrence Poree, director, Neuromodulation Service, Division of Pain Medicine at University of California, San Francisco (UCSF), USA, and the senior author of the publication, added, These are impressive clinical outcomes for comprehensively managing patients pain effectively over the long term. The more than 50% of closed-loop patients who reached high responder status of greater than or equal to 80% reduction in overall pain also demonstrated clinically meaningful changes in secondary patient-reported outcomes, emphasising the value of achieving this high threshold.

As clinicians, we understand that functional disability, emotional functioning, sleep quality, quality of life, and global impression of change are all extremely important to patients in managing their pain. One of the most notable patient-reported outcomes of the Evoke study was the voluntary reduction or total elimination of opioids by more than half of patients treated with closed-loop SCS. We believe that publication in the top neurology journal both shows the advantage of closed-loop spinal cord stimulation and demonstrates how this promising new therapy may benefit patients.

Key results published from the Evoke US pivotal study at 12 months include:

Results of the study through 3-months of follow-up were reported previously during multiple plenary and oral presentations by leading pain specialists at the International Neuromodulation Society (INS) 14th World Congress in Sydney.

John Parker, CEO of Saluda Medical, commented, We are now reaching a major junction, similar to that of the evolution of the cardiac pacemaker, where for the first time, we can record and respond to patients individual spinal cord electrophysiology continuously and in real time, providing adjustments millions of times per day and faster than any patient can adjust or predict. We are very pleased with this publication and its implications for future clinical potential.

Read more from the original source:
Results of US Evoke pivotal study published in The Lancet Neurology - NeuroNews International

Neurology & Neurosurgery Services l Neurology l University …

Posted on by

UH Neurological Institutes centers of excellence are focused on investigating and developing advanced treatments for neurological disorders. The following list includes a link to each center:

The internationally known specialists at UH Neurological Institutes Brain Health & Memory Center are at the forefront of research, diagnosis and treatment of a variety of memory and cognitive disorders. With a commitment to holistic patient care, our multidisciplinary team provides cutting-edge evaluation and advanced therapies for patients suffering from conditions such as Alzheimers disease, Parkinsons disease, dementia and short- and long-term memory loss. Our team is leading the way in research, both in learning more about certain neurological diseases and developing promising new therapies to treat various disorders. The Brain Health & Memory Center is also committed to providing support, assistance and resources to help families dealing Alzheimers and other conditions.Learn more about how we treat brain health and memory disorders.

University Hospitals Neurological Institutes Brain Tumor & Neuro-Oncology Center offers the most advanced diagnostic and treatment services for adults and children with both benign and malignant brain tumors. Our experts collaborate with the nationally recognized specialists at University Hospitals Seidman Cancer Center and develop highly personalized treatment plans for every patient. Patients can also participate in clinical trials that give them access to new treatments that may not be available at other hospitals.Learn more about how we treat brain tumors.

UH Neurological Institutes Community Neurology Center provides patients with all the expertise, services and testing of our Institute at convenient, close-to-home locations. The neurologists and neurosurgeons at our community facilities have access to a team of other specialists to help diagnose and treat a variety of neurological disorders. Combined with state-of-the-art technology for diagnostics and treatment, our integrated approach ensures that each patient receives comprehensive, individualized care. The Community Neurology Center services include back, spine and brain surgery, and treatment for conditions such as Alzheimers disease, epilepsy, fibromyalgia, multiple sclerosis, migraines and stroke.Learn more about how we treat general neurological conditions.

UH Neurological Institutes Comprehensive Stroke Center has the countrys highest designation available for stroke centers, and it is the largest and most experienced program in northeast Ohio dedicated to caring for stroke patients. Partnered with Case Western Reserve Universitys School of Medicine, our experts are engaged in research aimed at improving care. Our physicians specialize in managing diseases in patients who are high-risk and our rehabilitation specialists use state-of-the-art techniques to help speed up recovery.Learn more about how we treat stroke and neurovascular conditions.

The Epilepsy Center at the UH Neurological Institute is nationally recognized as one of the best in the country for treating seizure disorders in both adults and children. Our epilepsy specialists take an integrated, patient-based approach to care, evaluating each case and devising a treatment plan that will work best for each patient. The centers researchers have pioneered new medical therapies and surgical procedures for epilepsy, and clinical trials allow patients to have access to some of the newest, most innovative treatments around. Working hand in hand with Case Western Reserve School of Medicine and University Hospitals Rainbow Babies & Childrens Hospital, the Epilepsy Centers goal is to help patients live seizure-free lives by providing them with world-class care.Learn more about how we treat epilepsy.

UH Neurological Institutes Functional & Restorative Neurosurgery Center is dedicated to the restoration of function affected by neurological disease and the development of new technologies to improve brain health and optimize the quality of life for patients with neurological disease or disorders. Learn more about ourFunctional & Restorative Neurosurgery Center.

University Hospitals Multiple Sclerosis and Neuroimmunology Program diagnoses and treats patients with Multiple Sclerosis (MS) and other neuroimmunological conditions. Learn how we treat multiple sclerosis and neuroimmunology disorders.

The Music and Medicine Center at UH Neurological Institute is a unique program dedicated to diagnosing and treating music-related injuries and medical problems. A collaboration between University Hospitals Cleveland Medical Center and Case Western Reserve University, the center uses coordinated efforts to advance the knowledge in the field of music and medicine. Through patient care and research, the Music and Medicine Center hopes to improve understanding on how music affects the body and to develop technology that will enhance health through music.Learn more about how we treat music related medical problems.

Critically ill patients with neurological or neurosurgical disease receive superior, specialized care at UH Neurological Institutes Neurocritical Care Center. Our staff of highly trained neurological and critical care specialists uses the most advanced techniques and technology to treat patients, providing exceptional care while placing emphasis on the patient and his or her individual needs.Learn more about how we treat conditions that requireneurocritical carepatients.

The Neurological & Behavioral Outcomes Center is a collaboration between UH Neurological Institute and Case Western Reserve University School of Medicine and is devoted to analyzing and improving patient outcomes. Our team of leading neurological specialists utilizes some of the latest innovations in clinical care. The center is working to advance patient care in the areas of brain tumors, epilepsy, memory and cognition and stroke.Learn more about ourNeurological & Behavioral Outcomes Center.

UH Neurological Institutes Neuromuscular Center is one of the top institutions in the country for treating a host of complex neuromuscular and autonomic disorders. Led by some of the most respected physicians in the field, the Neuromuscular Center offers innovative diagnostic and therapeutic services for conditions such as muscular dystrophies, Guillain-Barre Syndrome and ALS (Lou Gehrigs Disease). Our team is dedicated to providing comprehensive care to help improve our patients quality of life.Learn more about how we treat neuromuscular conditions.

The Neuropsychiatry Center at UH Neurological Institute specializes in treating psychological problems that can occur in patients with neurological disorders. Our nationally recognized neuro-psychiatrists provide high-quality care for both adults and children who suffer from such co-occurring disorders, helping to improve function and reduce the rates of complications.Learn more about how we treat neuropsychiatric conditions.

The goal of the Neuroscience Nursing Practice Center is to research, develop and apply the most advanced neuroscience nursing practices available in order to provide patients with a superior level of care. The center is dedicated to bridging the gap between research and clinical practice, providing patients with the tools and support they need and developing relationship for improved outcomes. Our clinical staff strives to apply these neuroscience nursing techniques through every step of the treatment process, from initial diagnosis through follow-up visits.Learn more about ourNeuroscience Nursing Practice Center.

The Parkinsons & Movement Disorders Center is dedicating to diagnosing, evaluating and delivering therapeutic services for a range of neurological movement disorders. The longest-running program in Ohio devoted solely to movement disorders, our specialists care for patients with conditions such as Dystonia, Essential tremors, Huntingtons disease, Parkinsons disease, spasticity and Tourette syndrome.Learn more about how we treat movement disorders.

Here is the original post:
Neurology & Neurosurgery Services l Neurology l University ...

Human Resources / Benefits / Workers’ Compensation / Panel

Posted on by

Foot & Ankle Institute**

School of Podiatric Medicine

3223 North Broad Street, Suite 150

Philadelphia, PA 19140

-or-

8th & Race Streets

Philadelphia, PA 19107

215-238-6600

General Surgery Department**

Temple University Hospital

3401 North Broad Street, Suite 466

4th Floor, Parkinson Pavilion

215-707-3133

Kornberg School of Dentistry**

Meredith Bogert, D.M.D.

3223 North Broad Street

2nd Floor

Philadelphia, PA 19140

215-707-5934

Neurology Department**

Temple University Hospital

3401 North Broad Street, Suite 525

5th Floor, Parkinson Pavilion

215-707-3040

Neurosurgery Department**

Temple University Hospital

3401 North Broad Street, Suite 540

5th Floor, Parkinson Pavilion

215-707-7200

Ophthalmology Department**

Temple University Hospital

3401 North Broad Street, Suite 640

6th Floor, Parkinson Pavilion

215-707-3185

-or-

Temple University Main Campus

1932 Liacouras Walk

Philadelphia, PA 19122

215-204-5636 / 215-204-5637

Orthopaedic Surgery, Sports Medicine and Physical Therapy**

Temple University Hospital

3509 North Broad Street

5th Floor, Boyer Pavilion

215-707-2111

http://www.templeortho.net

Physical Medicine/Therapy and Rehabilitation**

Temple University Hospital

3401 North Broad Street

Basement, Rock Pavilion

215-707-3646 / 215-707-2997

Temple Total Therapy (T3)

Steven J. Pettineo, MPT, DPT, CSCS

8th & Race Streets

Philadelphia, PA 19107

215-238-6600 / 215-629-4905 (FAX)

Plastic and Reconstructive Surgery**

Temple University / Fox Chase Cancer Center

3322 North Broad Street

3rd Floor

Philadelphia, PA 19140

215-707-3935

Radiology**

(X-Rays, MRIs, and CT Scans)

Temple University Hospital

3401 North Broad Street

1st Floor, Parkinson Pavilion

215-707-XRAY (9729)

Tanenbaum & Associates Psychology

Robert L. Tanenbaum, Ph.D.

111 Presidential Boulevard, Suite 131

Bala Cynwyd, PA 19004

610-664-3442

Wahner Chiropractic

Barry A. Wahner, D.C.

4931 Wissahickon Avenue

Philadelphia, PA 19144

215-842-2227

http://www.drwahner.com

Read the original post:
Human Resources / Benefits / Workers' Compensation / Panel

High rates of dementia, Alzheimer’s observed among older people with Down syndrome – National Institutes of Health

Posted on by

News Release

Monday, October 28, 2019

NIH-funded study highlights need for research on aging Down syndrome population.

A study of Wisconsin Medicaid enrollees with Down syndrome has found that more than half of those ages 55 and older have filed at least three claims for dementia and nearly a third have filed at least three claims for Alzheimers disease. The analysis was funded by the National Institutes of Health and the Agency for Health Care Research and Quality, and it appears in JAMA Neurology.

People with Down syndrome are at higher risk for dementia as they age. The study authors noted that nearly all adults with Down syndrome develop neurological changes by age 40, but symptoms may not appear for decades. The authors added that population studies are needed to identify when symptoms begin so that families and health care systems can plan care for people with Down syndrome as they age.

In the current study, researchers led by Eric Rubenstein, Ph.D., and colleagues at the University of Wisconsin-Madison analyzed claims records by 2,968 Wisconsin Medicaid enrollees with Down syndrome from 2008 to 2018. Among those ages 40 to 54, 18.8% (190 of 1013) had filed dementia claims. There was a 40% chance that a person with Down syndrome age 40 to 54 years old would file a dementia claim over the next 11 years; there was a 67% chance that a person with Down syndrome age 55 or older would file such a claim. Among men and women with Down syndrome younger than 40, the likelihood of dementia was roughly equal, but from ages 40 to 54, dementia was 23% more likely in women.

Because eligibility requirements for people with Down syndrome are similar among Medicaid programs, other states may likely have a comparable proportion of claims for dementia and Alzheimers disease in this population.

NIH funding for the study was provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Center for Advancing Translational Sciences.

Melissa Parisi, M.D., Ph.D., chief of the NICHD Intellectual and Developmental Disabilities Branch, is available for comment.

Rubenstein, E. Research Letter: Epidemiology of dementia and Alzheimers disease in individuals with Down syndrome. JAMA Neurology.2019.

About theEunice Kennedy ShriverNational Institute of Child Health and Human Development (NICHD): NICHD conducts and supports research in the United States andthroughout the world on fetal, infant and child development; maternal, child and family health; reproductive biology and population issues; and medical rehabilitation. For more information, visitNICHDs website.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

See original here:
High rates of dementia, Alzheimer's observed among older people with Down syndrome - National Institutes of Health

Neurology and Rehabilitation Medicine

Posted on by

Faculty and Staff Search Select a member name TYPE IN NAMEAgrawal, Garima Ahmed, Faisal Andersen, Emerlee Arthur, Todd Arya, Ravindra Awosika, Oluwole OladimejiBaba Ahmed, Nassima Backeljauw, Barynia FBaker, Margaret J.Bakk, Ian Barrett, Edwin T.Belotserkovskaya, Natalya AleksandrovnaBernert, Silke AndreaBlankenship, Rachel Bolger, Ashlee Bouman, Dawn EBowman, Michelle Bratt, Robin EBroderick, Joseph P.Broomall, Eileen Bruns, Jason MBurns, Timothy Byars Weber, Anna M.Caine, Rebecca Callow, Mark AngeloCapal, Jamie Cavitt, Jennifer L.Chicoine, Caitlin LeeClark, Joseph FColapietro, Patricia MColeman, Elisheva RuthCollins, James Darko, Isaac Davalos, Long Deaton, Lois LDemel, Stacie LDeSena, Allen Devoto, Johnna LDragan, Elizabeth MarieDuke, Mary Duker, Andrew P.Duplechan, Lester ShermanDye, Thomas Espay, Alberto J.Evanson, Nathan KFerioli, Simona Ficker, David M.Flaherty, Matthew L.Foreman, Brandon Foster, Forrest Franz, David N.Franz, Janet SueGarrison, Graham Gartner, Maureen Gaskey, John AGates, Christine AGilbert, Donald Girmann, Jeremy Glauser, Tracy AGoddard, Mark josephGoldstick, Lawrence phillipGoranovich, Justin TymeGreiner, Hansel Gross, Christina Grossman, Aaron Guerra, Felix Gusler, Matthew Haas, Kimberly AnnHallinan, Barbara E.Hartshorn, Jonathan Heil, Jason WilliamHentz, Rhonda SueHergert, Laura M.Hershey, Andrew D.Holland, Katherine Horn, Paul SHorning, Sheena Marie GaleaHosseini, Shahla Huynh, Margaret Illingworth, Alexa Ann Jacob, Cara Jain, Sejal Janecek, Jacqueline Jasne, Adam ScottJensen, Pamela Jewell, George RJohns, Christopher AKacperski, Joanne Kadis, Darren SKanter, Daniel S.Kastner, April JKatz, Brian SKhatri, Pooja Kinnett, Douglas GKircher, Charles Kissela, Brett M.Kleindorfer, Dawn OKrueger, Darcy Kurowski, Brad Kushlaf, Hani Kwon, Soo Young Lee, Ikjae Loren, Brenda PLowe, Forrest Lupidi, Kayla AnnMacDonald, Jessica AnnMajd, Nazanin KoohbananiMalik, Sheetal Martin, Joshua Massey, Andrew McClain, Travis ForesteMcFarland, Walter McKee, Heather McMahon, Mary AnnMelchert, John JordanMerola, Aristide Meziane-Tani, Assia Mistry, Eva Mitchell, Charles HughMizrahi, Moshe AlbertMolano, Jennifer Rose Morita, Diego Moseley, Brian DMullins, Joyce L.Neel, Robert Nicolas, Joseph A.Nobunaga, Austin INorman, Jensine' JuanitaNurre, Emily RachaelObeidat, Ahmed O'Brien, Hope LorraineO'Hara, Devin Pajor, Holly Kay AsmussenParawira, Sandra Paulson, Andrea Peariso, Katrina Pedapati, Ernest Plancher, Joao Mc-O'Neil Privitera, Michael DPruitt, David Quarles, Glenn RichardQuinlan, John GRankin, Jess RRitter, Stephanie AnnRizik, Bridget Roller, Stephanie LaurenRose, Douglas Ryan, Alyson RochelleRybalsky, Irina Sahay, Alok Samaha, Marielle KabboucheSams, Laura Ann Santia, Christina LouiseSathe, Mahima S.Sawyer, Russell Schapiro, Mark BSchoner, Angela PSeals, Shannon Selm, Lori AnnSeroogy, Kim B.Shah, Reena Sharma, Sameer Shatz, Rhonna ShellyShear, Paula K.Shen, Jack Shirani, Peyman Shoreman, Danielle MarieSiroky, Brian Situ, Luis MiguelSkelton, Matthew Smith, Daniel Smith, Matthew Standridge, Shannon Stanton, Robert JosephStillwagon, Angela Subbiah, Bakkiam Sutton, Mary Taylor, John M.Tenney, Jeffrey Thomas, Cameron Tian, Cuixia Tomsic, Steve Turner, Ashby ClayUnkrich, Deborah SVallin, Eileen CatherineVan Sanford, Carson DavidVannest, Jennifer JVarga, Scott Vargus-Adams, Jilda Vaughan, Jennifer ElizabethVenkatesan, Charulata Vij, Brinder Villegas, Melissa AnneVorhees, Charles V.Wade, Shari Walsh, Kyle Wang, Mei Waters, Brandon LeeWead, Douglas MWesselkamper, Kristen RWilliams, Michael TWolf, Stefanie Wong, Brenda Woo, Daniel Wood, Christopher Wrigley, Peter Wu, Steve Xiang, Jing Yacyshyn, Marianne HZabeti, Aram Zaghlouleh, Muhammad Zaidi, Syed Zale, Chelsea Zhu, Julia

For a comprehensive search, select from one of the following:

Continue reading here:
Neurology and Rehabilitation Medicine